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INTRODUCTION
One of the most delicate and specialised structures of the eye is the retina. The retina is 
a light-sensitive layer that converts the light that falls onto it into an electrical signal. 
Subsequently, the electrical signal travels through the optic nerve and optical radiation to 
the visual cortex where it is translated into an image. 
In the retinal structure we can distinguish ten layers. The innermost layer is the internal 
limiting membrane (ILM), followed by the nerve fibre layer, ganglion cell layer, inner 
plexiform layer, inner nuclear layer, outer plexiform layer, outer nuclear layer, external 
limiting membrane, the photoreceptor layer and the retinal pigment epithelium (RPE). The 
first nine layers are collectively called the neurosensory retina. Although the neurosensory 
retina is strongly attached at the edges of the optic nerve head and the ora serrata region 
(the anterior edge of the neurosensory layer), the adhesion to the underlying RPE is weaker. 
The nutrition of the inner layers of the retina is supplied by the central retinal artery and its 
branches, which enter the eye through the optic nerve. The metabolism of the outer layers 
of the retina is further supported by the underlying choroid vessels and the sclera (see 
Figure 1). 
THE VITREOUS
Approximately 80% of the volume of the eye contains the vitreous. The vitreous is a clear 
matrix composed of collagen, hyaluronic acid, and water. The vitreous is most firmly 
attached to the vitreous base but it is also firmly attached to retinal vessels, the optic nerve, 
and the macula. With ageing (starting already at the age of 2 years), the vitreous humour 
Figure 1. Anatomy of the eye.  |  © Pearson Education
201749 proefschrift Verena Mulder_new_2.indd   10 09-02-18   12:43
11
I NTRODUCTION
1
starts to liquefy. While it first filled the whole cavity, the vitreous gel eventually starts to 
shrink, putting various portions of the retina under tractional stress. When the posterior 
vitreous starts to detach from the retina – called a posterior vitreous detachment or PVD 
– the tractional stress can become too much and produce a tear or hole in the neurosensory 
layer.1 
RHEGMATOGENOUS RETINAL DETACHMENT
The separation of the neurosensory layer from the underlying RPE is called a retinal 
detachment. In the case of a rhegmatogenous retinal detachment (RRD), the cause of the 
detachment is a tear or hole in the retina, implied by the Greek word rhegma, which allows 
fluid from the vitreous cavity to flow into the subretinal space resulting in the separation 
of the layers (Figure 2).2, 3 
Patients with a retinal detachment usually experience floaters (mouches volantes), light 
flashes and – dependent on the extent of the detachment – visual field loss and/or loss of 
vision. Nearly all patients with symptomatic RRD will progressively lose vision and will 
eventually become blind when left untreated.2, 3 
The incidence of RRD is approximately 18 per 100 000 people and increases significantly 
with age, with the mean age being 60 years.3-5 Besides age, other risk factors include high 
myopia, male gender, trauma, cataract surgery, a retinal detachment in the other eye or a 
family history of retinal detachment.2
SURGICAL TREATMENT 
Treatment of RRD consists of closing the retinal break and relieving vitreous traction on the 
retina. To accomplish this, the surgeon can either choose an external or internal approach. 
The external approach consists of suturing a silicone encircling band and/ or segmental 
silicone explant onto the sclera. By using mattress sutures wider than the explant material 
the resulting indentation causes relief of traction internally at that exact point. This procedure 
can be combined with external drainage of subretinal fluid and the injection of air or gas 
Figure 2. Schematic representation of a rhegmatogenous retinal detachment. Normally the posterior segment 
is completely filled with vitreous (grey) (1). With ageing the vitreous liquefies and shrinks slowly (2), it detaches 
from the retina (pink). This posterior vitreous detachment (PVD) sometimes leads to a tear in the retina (3). 
When fluid flows into the subretinal space the retina detaches (4). Adapted from: www.oogziekenhuis.nl
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to temporarily close the retinal tear and approximate the neurosensory layer to the RPE. 
Laser photocoagulation or cryopexy can be added to create a chorioretinal burn to induce 
adhesion by reactive scarring. 
The internal approach is by pars plana vitrectomy (PPV). This approach involves the surgical 
removal of the vitreous gel as a source of retinal traction. The surgical instruments enter 
the eye through three ports in the pars plana. After removal of the vitreous gel up to its 
adhesion in the vitreous base, the eye is usually filled with a tamponade to close retinal 
breaks and approximate the neurosensory layer to the RPE and to maintain intraocular 
pressure (IOP). Frequently used tamponades are gas (SF6, C3F8) or silicone oil (1000 or 
5000 centistoke viscosity). 
COMPLICATIONS 
Both scleral buckling (SB) and vitrectomy have their advantages and disadvantages. The 
scleral buckling procedure can lead to a change in refractive error and is associated with 
complications including diplopia, choroidal detachment, and perforation of the sclera when 
suturing the explants or draining subretinal fluid. Vitrectomy may avoid some of these 
complications, but it carries a higher risk of endophthalmitis and glaucoma, and leads to 
cataract formation.6 
Anatomical reattachment is accomplished with a single surgery in 80-90% of patients.6 In 
patients where the primary surgery fails, reoperation results in final reattachment rates 
around 96%.6 The most frequent cause of the need for reoperation – due to persisting or 
recurrent detachment – is a missed or new retinal break which in general can be treated 
successfully. The primary cause of failure of reattachment despite multiple interventions 
is the development of proliferative vitreoretinopathy. 
PROLIFERATIVE VITREORETINOPATHY
Proliferative vitreoretinopathy (PVR) is characterised by the growth of contractile membranes 
on or under the retina, or fibrosis within the retina that causes detachment of the 
neurosensory layer from the underlying RPE (Figure 3). PVR develops in 5-10% of patients 
and is still the most severe and most difficult complication of RD to treat because these 
membranes are very difficult to remove completely without further damaging the 
neurosensory layer and moreover have the tendency to recur.7 PVR can develop in eyes 
with RRD if the detachment remains untreated for a period of weeks to months but it more 
typically occurs in eyes that have undergone retinal reattachment surgery. Its onset is 
usually 2 weeks to 6 months after surgery, with a median of 2 months.8 
PATHOPHYSIOLOGY
After detachment of the neurosensory layer from the RPE, the outer retinal layers become 
ischemic. Due to activation of intrinsic protective mechanisms, this does not lead to 
immediate neurone death but after cessation of the initial stress response will.7 
Subsequently, glial cells initiate a nonspecific tissue repair response that involves 
inflammation and proliferation that finally leads to remodelling of the retina.7 
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Although these responses are part of normal tissue healing, in 5-10% of patients these 
responses progress to the development of PVR. What critical distinctive difference is 
present to direct these events towards PVR is yet unclear.
Under physiologic conditions, RPE is organised as a monolayer of hexagonal shaped cells 
densely packed together and constitutes an important part of the blood-retinal barrier. 
However, after tissue injury such as in RD, RPE cells may detach from their normal 
attachment to Bruch’s membrane and start to proliferate while undergoing transformation.7, 
9 This transformation is called epithelial-mesenchymal transition (EMT). The RPE cell loses 
its epithelial features such as tight junction molecules, and acquires mesenchymal features 
that include enhanced migratory capacity, invasiveness, resistance to apoptosis, and 
production of extracellular matrix (ECM) components.7, 9-11 The now myofibroblast-like cells 
migrate into the vitreous through breaks in the retina. With the blood-retinal barrier 
breakdown (see Blood-Ocular Barriers) the cells are exposed to inflammatory mediators 
such as C-C motif chemokine ligand (CCL)2, C-X-C motif chemokine ligand (CXCL)8, 
granulocyte-macrophage-colony-stimulating factor (GM-CSF), interleukin (IL)-6 and IL-8, 
growth factors, and ECM.  Tissue damage also triggers the recruitment of monocytes and 
macrophages, which in their turn are able to produce pro-fibrotic mediators such as PDGF, 
TGFβ, and VEGF. Myofibroblasts exhibit contractile properties and a strong capacity to 
produce ECM molecules such as collagen, elastin, laminin, fibronectin, and vitronectin. 
The interplay of all these factors finally leads to the development of contractile membranes 
and formation of fixed folds in the retina. 
Figure 3. Total RRD with severe PVR. This image 
was originally published in the Retina Image Bank 
by Darin R. Goldmann. 2015; # 25035.
© the American Society of Retina Specialists.
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PHARMACOLOGIC PREVENTIVE AND ADJUVANT THERAPY 
In general, pharmacological attempts to prevent PVR have focused on either interfering with 
proliferation or modifying the inflammatory cascade. One of the first types of drugs tested 
for PVR were corticosteroids. Corticosteroids are widely used for a variety of conditions and 
exert anti-inflammatory properties. However, despite success in animal models of PVR, 
studies in patients failed to demonstrate the same beneficial effect. An intravitreal injection 
of 2-20mg triamcinolone acetonide did not improve outcomes in patients undergoing 
vitrectomy with silicone oil for PVR.12-15 A preoperative injection of dexamethasone 
diphosphate showed a decrease in laser flare measurements at 1 week postoperatively. 
This suggested that steroid priming might be useful in reducing BRB breakdown and hence 
PVR. However, the follow-up period in this study was short.16, 17 Oral prednisone 1mg/kg 
during 10 days did not improve reattachment rate, visual acuity, PVR, or postoperative 
complications.18 A 15-day oral prednisone regimen tapered from 100mg to 12.5mg did 
significantly reduce the formation of cellophane membranes compared to placebo.19 
Until recently, proliferation RPE and glial cells were seen as one of the main features of 
PVR.7 Therefore, most proposed therapies are aimed at inhibiting cell proliferation. A 
frequently tested combination in patients is the antimetabolite 5-Fluorouracil (5-FU) and 
a Low-Molecular-Weight Heparin (LMWH), usually dalteparin or enoxaparin.20-24 These 
drugs were added to the vitrectomy infusion fluid in concentrations of 200 µg/ml and 5 IU/
ml, respectively, and exposure was approximately 1 hour.25 5-FU inhibits DNA synthesis 
and fibroblast proliferation, while LMWHs are thought to inhibit fibronectin and prevent 
fibrin formation.26 Although LMWHs have reduced tendency to bind macrophages and 
plasma proteins – including vitronectin, fibronectin, and fibrinogen – compared to the large 
negatively charged molecule heparin, effects on fibrin formation and reduction of tractional 
detachment have been demonstrated.27, 28 However, randomised controlled trials showed 
little efficacy. 
A second antineoplastic agent tested in patients with advanced preoperative PVR is the 
anthracycline daunorubicin. In a randomised controlled trial of 286 patients it was infused 
intravitreally over a 10 minute period (7.5 µg/ml) before a tamponade was injected.29 The 
authors found no significant difference in reattachment rate at 6 month postop but the 
daunorubicin group needed fewer reoperations in the first year. 
Colchicine, which is normally used in gout treatment, was tested in patients with RRD 
undergoing SB. Patients were randomly assigned to oral colchicine 1mg twice daily for 7 
weeks or placebo.30 Colchicine had shown an effect in an animal study, but in a double-
masked controlled trial of 184 patients, no effect was found on the prevention of retinal 
detachment due to PVR.31   
Oral 13-Cis-retinoic acid (isotretinoin) has been tested in two different administration 
schemes in patients undergoing surgery for PVR. In the first retrospective study, isotretinoin 
was used for 4 weeks in a dosage of 40mg twice daily in combination with oral prednisone 
1mg/kg for 3 weeks followed by a taper over the subsequent 3 weeks. Although the study 
population was small (n = 20) it showed some encouraging results.32 In the second 
prospective randomised controlled study (n = 16/19), the treatment period was prolonged 
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to 8 weeks and the isotretinoin dose was lowered to 10mg twice daily, no prednisone was 
used.33 The results showed a significantly higher initial and final repair rate with isotretinoin. 
Neither of the two studies was placebo controlled.   
A different type of drug tested in humans was the DNA-RNA chimeric ribozyme VIT100, 
which targets proliferating cell nuclear antigen (PCNA). Inhibition of this cell cycle controlling 
gene that inhibits cell division was not effective in preventing PVR recurrence in a double-
masked, placebo-controlled, randomised clinical trial that enrolled 154 patients with 
established PVR.17  
Other drugs tested in vitro or in experimental PVR are the antineoplastic agents etoposide, 
tacrolimus, paclitaxel, vincristine, cisplatin, doxorubicin, mitomycin, and actinomycin D, the 
kinase inhibitors hypericin, herbimycin A, alkyl phosphocholine, fasudil and AG1295, the 
TGFβ inhibitor tranilast, the TNFα blocker adalimumab, the anti-fibrotic drug pirfenidone, 
the antiprotozoal suramin, the antioxidant N-acetylcysteine, the cholesterol-lowering drug 
simvastatin, and glucosamine.7, 17 More recently, the antiangiogenic drugs ranibizumab and 
aflibercept have been added to the list.7 
Most drug therapies have been tested in patients in combination with membrane removing 
surgery. In these patients, the processes involved in PVR development are fully active and 
possibly difficult to reverse. Ideally, one would like to have a prophylactic treatment and 
interfere in this process before it even starts. 
COAGULATION PROTEINS
Activation of the coagulation cascade after tissue injury is crucial in facilitating the healing 
process. However, uncontrolled activation of the coagulation cascade has been recognised 
to contribute to fibrosis.34, 35 In the case of RD, RPE cells are exposed to serum factors as 
shown by the procoagulant activity in subretinal fluid from patients with RRD because of 
the damage in the blood-retinal barriers (see Blood-Ocular Barriers).36 In his thesis, “A novel 
role for coagulation proteins in the development of proliferative vitreoretinopathy”, 
Bastiaans et al showed that the cellular processes activated by the coagulation factor 
thrombin contribute to the development of PVR and that thrombin is a possible new target 
for therapy. 
BLOOD-OCULAR BARRIERS 
Nutrients and other substances – either endogenous or administered – can enter the eye 
through the vessels in the stroma of the iris and pass into the newly formed aqueous 
humour. The cornea is exposed to substances from the limbal capillaries and the aqueous 
humour as well as from the tear layer. The retina and vitreous body are served by either 
the choroidal or retinal circulation, and to a lesser extent by the aqueous in the posterior 
chamber, the space behind the lens. 
To protect the eye from potentially damaging agents and to maintain homeostasis, the eye 
exploits a variety of mechanisms including tear secretion, an active transport system 
pumping potentially damaging agents from the retina back into the bloodstream, and several 
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barriers to prevent diffusion from the bloodstream into the eye (see Figure 4).37
The two most important barriers are the blood-aqueous barrier (BAB) and the blood-retinal 
barrier (BRB), collectively called the blood-ocular barriers (BOB). As the name implies, the 
blood-aqueous barrier regulates exchanges between the blood and aqueous humour. It is 
comprised of a non-pigmented epithelial layer of the ciliary body and an endothelial layer 
in the blood vessel walls of the iris.38 These cell layers exclude blood proteins that would 
impair transparency and disturb the osmotic and chemical equilibrium.  
The blood-retinal barrier consists of tight junctions between the endothelial cells of the 
retinal vessels (the inner blood-retinal barrier) and of tight junctions between the RPE cells 
(the outer blood-retinal barrier). In addition, certain enzymes reside in the endothelial and 
epithelial cells which contribute to the protective function. These enzymes include 
Angiotensin Converting Enzyme (ACE), dopa decarboxylase, γ-GTP, pseudocholinesterase, 
and monoamine oxidases.38
BLOOD-OCULAR BARRIERS AND DRUG DELIVERY
The presence of the BOBs greatly influences the delivery of drugs into the eye. In addition, 
the clearing mechanisms complicate maintaining an adequate drug level. For example, the 
cytochrome p-450 drug metabolising system and the efflux pump P-gp have been identified 
in RPE.37, 39  
The properties of the drug are therefore of importance. Molecules with higher lipid solubility 
penetrate cell membranes more easily and this is also true for cellular layers. In addition, 
a smaller molecular size and a charge aid in diffusion.     
Figure 4. Schematic representation of the Blood-Ocular Barriers. A= Aqueous humour; C= Cornea; D= tear 
fluid; H= posterior chamber; I= Iris; L= Lens; S= Sclera; V= Vitreous; Z= Ciliary body  
Adapted from Maurice DM, Mishima S. Pharmacology of the Eye; Handbook of Experimental Pharmacology. 
Vol.69 ed. Germany: Springer-Verlag Berlin Heidelberg New York Tokyo; 1984:736-21.
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Repeated topical application of drops and ointments is usually adequate for most external 
conditions and those of the anterior segment. Local injections are an option for reaching 
the posterior segment. They have the advantage of circumventing the eye’s natural barriers 
but carry the risk of endophthalmitis, especially with repeated administration. Administration 
via the systemic route is easier but suffers from the disadvantage that all the organs of the 
body are exposed to the drug when only a small volume of tissue in the eye needs the 
treatment.37
BLOOD-OCULAR BARRIER BREAKDOWN ASSOCIATED WITH DISEASE 
In disease, inflammatory mediators cause tight junctions to disappear leading to increased 
vascular permeability. It has been shown by anterior segment fluorophotometry (ASFM) 
that the BAB is significantly more permeable in RRD.40 
As described earlier, RD also leads to disruption of the BRB. This breakdown of the BOB 
barriers makes the eye more susceptible to systemic substances and opens up the 
possibilities for systemic drug treatment.
It was also shown however that the BAB permeability returned to normal within two 
months of successful reattachment of the retina.40 
LASER FLARE PHOTOMETRY
Under normal conditions, the anterior chamber is an optically empty space which facilitates 
optimal visual function. When the eye becomes inflamed, however, disruption of the BAB 
leads to leakage of proteins and inflammatory cells into the anterior chamber.41 Increased 
protein content in the anterior chamber produces an optical phenomenon called flare (or 
Tyndall effect).42 Flare can be compared to the effect produced by a narrow beam of light 
crossing a dark smoky room.42 
Clinicians examine the severity of inflammation by slit-lamp biomicroscopy of the aqueous 
humour, and they grade the amount of flare on a scale from “faint” to “intense”.43, 44 This 
type of examination gives at best semi-quantitative values, because it highly relies on light 
conditions, the experience of the examiner, and contrast sensitivity of the examiner’s eye.45 
In 1989 Kowa company marketed their first laser flare cell meter (FC-1000). This instrument 
was able to quantify flare and cells by using a laser. Laser flare offered an objective, 
reproducible and non-invasive measurement technique to assess inflammation.
WORKING PRINCIPLE (FM-500)
Laser flare photometry quantifies aqueous humour protein by measuring the amount of 
light scattered by the proteins in the anterior chamber. The light source is a semiconductor 
diode laser (650nm) which is placed at a 90⁰ angle from the light receiving device (a 
photomultiplier).46 During the measurement, a small window of 0.3mm x 0.5mm is scanned 
over 0.5 seconds. In addition, it records two background measurements from above and 
below this window, which is regarded as noise from surrounding ocular tissues. The flare 
count is then obtained by subtracting the average of the two background readings from 
the main signal (see Figure 5). 
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CLINICAL APPLICATION 
Since the introduction, laser flare measurements have mainly been used to monitor disease 
activity in diseases such as uveitis and retinitis pigmentosa.44, 47-51 In addition,  laser flare 
has been used to follow up on inflammation after surgical procedures such as cataract 
extraction, vitrectomy, and scleral buckling.16, 52, 53 It was found not only to be useful in 
monitoring the anterior segment but also of the posterior segment.44, 45, 49, 54-56 
Figure 5. On the left: the laser beam passing the cornea and anterior chamber. On the right: the output of 
a typical flare measurement.
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THIS THESIS
It is still not completely understood why some patients develop PVR and others do not 
despite extensive research on cytokine biomarkers, genetic profiles and ocular clinical risk 
factors. Recently, a new possible treatment target was proposed based on studies on the 
role of coagulation proteins in the development of PVR. 
While several pharmaceutical drug therapies have been proposed for PVR – targeting 
inflammation, proliferation and growth factors – these drugs all have potential side effects. 
Therefore, to optimise the benefit/risk ratio of drug therapies, it is crucial to select only 
those patients at high risk of developing PVR 
In chapter 2 we tested whether the oral direct thrombin inhibitor dabigatran would be a 
potential drug candidate for the treatment of PVR. In this respect, we tested whether oral 
administration would lead to measurable levels in the eye (2.1 and 2.2) and whether 
dabigatran was able to oppose the effects of thrombin in an in vitro model (2.3). In chapter 
2.4 we tested the amount of endogenous thrombin generation and inhibition in vitreous 
and subretinal fluid. 
In chapter 3 we tested the applicability of aqueous humour laser flare measurements 
in distinguishing between patients at high and low risk of developing PVR. Firstly, we looked 
at preoperative flare values (3.1) and secondly at postoperative flare values (3.2). Chapter 
3.3 shows that the choice of surgery might also influence postoperative inflammation and 
thus influences the risk of developing PVR. 
An aspect that has gained less attention in research is the possible influence of concomitant 
systemic drug use. As mentioned earlier, the prevalence of RRD increases with age with 
a mean age around 60 years. In this age group, systemic drug use is not uncommon but 
little is known about the possible impact of these drugs on the eye. Of particular interest 
would be systemic drugs known to affect inflammation or fibrosis that could potentially 
have a stimulating or  a protective effect on the course and the occurrence of PVR. In 
chapter 4, we describe our research into whether medication use around the time of 
surgery for RRD was of importance for the development of PVR.  
After the summaries in chapters 5 and 6, chapter 7 will discuss our findings and future 
perspectives. 
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ABSTRACT
PURPOSE
Thrombin appears to play a role in the development of proliferative vitreoretinopathy, a 
complication of retinal detachment characterized by epiretinal membranes. A specific oral 
thrombin inhibitor, like dabigatran, might be a possible therapeutic option. It opens the 
possibility of prolonged administration in contrast to drugs that can only be applied during 
vitrectomy. We tested if dabigatran reaches the vitreous and subretinal fluid (SRF) after a 
single oral dose of dabigatran. 
METHODS
Twenty-eight patients with a rhegmatogenous retinal detachment received a single dose 
of 220mg dabigatran etexilate 2 to 8 hours prior to surgery. During surgery, we took a blood 
sample and depending on the type of surgery, a vitreous or subretinal fluid sample. The 
concentration of dabigatran was measured using LC-MS/MS. 
RESULTS
The dabigatran concentration in SRF between 2 and 9 hours after administration varied up 
to 8.5ng/mL. The concentration in the vitreous fluid was lower and varied up to 3.8ng/mL. 
Corresponding plasma concentrations ranged from 15ng/mL to 225ng/mL. There was a 
significant relationship between SRF levels and plasma levels (rs= .68, p=.014); the levels 
in vitreous fluid showed no such relationship (rs= .20, p=.48). In addition, we measured 
the vitreous concentration of a non-study patient using 150mg dabigatran BID. The 
concentration was 25.8ng/mL, approximately 10 times higher than after a single dosage. 
CONCLUSION
In conclusion, we demonstrate that oral intake of dabigatran, a candidate drug to modulate 
PVR, results in potentially relevant intraocular concentrations. We suggest that repeated 
dosing may lead to higher concentrations, but this should be further explored.
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INTRODUCTION
Dabigatran etexilate (Pradaxa®) is an oral prodrug that is metabolised by serum esterases 
to dabigatran. Dabigatran is a competitive and reversible direct thrombin inhibitor used to 
decrease the risk of venous thromboembolic events in patients undergoing hip or knee 
replacement surgery.1
Apart from its role in the coagulation cascade, thrombin appears to play a role in the 
development of proliferative vitreoretinopathy (PVR) – a complication that is seen in 
approximately 10% of patients after surgery for a retinal detachment –  inhibition of 
thrombin might be a possible therapeutic target for prevention of PVR.2 It opens the 
possibility of prolonged administration in contrast to drugs that can only be applied during 
vitrectomy. 
The main challenge of an oral drug is to achieve effective drug levels in the posterior 
segment of the eye. Ideally over a sustained period of time, as PVR is a process that 
typically develops during first 6 weeks after a retinal detachment. A healthy eye is protected 
from potentially damaging agents by barriers to diffusion and an active transport system 
clearing the retina, but these mechanisms also prevent effective drug concentrations in 
the ocular tissues when administered through the circulation.3
In the past several anti-inflammatory agents, antiproliferative agents and heparin have been 
clinically tested for their disease-modifying effect on PVR, as single agents as well as in 
combination. Most of these drugs were administered perioperatively in the vitrectomy 
infusion fluid or locally by intravitreal injection. Exposure to these drugs was relatively short 
with at best modest results on PVR modulation.4-9 Prolonged local exposure by repeated 
intravitreal injections might be more effective than oral administration but is less attractive 
in terms of infection risk and convenience for the patient.
In case of a retinal detachment, the blood-retinal barrier might be (partially) disrupted, 
making the eye more permeable to systemic drugs. Dabigatran is a small polar molecule 
of approximately 471 Dalton with a great likelihood of passing the blood-retinal barrier in 
case of a rhegmatogenous retinal detachment. The maximum time-concentration point in 
vitreous and subretinal fluid is difficult to predict as there is little knowledge about the ratio 
between serum and eye concentrations. Weijtens et al. conducted a bioavailability study 
of different administration routes of dexamethasone, which has a similar molecular weight 
as dabigatran.10 Although dexamethasone differs in lipophilicity from dabigatran (LogP 1.93 
vs -2.4), it is the best comparison available. Weijtens et al. found a 15 times and 7.5 times 
lower concentration of dexamethasone in vitreous and subretinal fluid respectively than in 
serum. It has been reported that a single administration of 200 mg dabigatran etexilate 
resulted in a maximum concentration of 161 ng/mL in plasma.11 In analogy with 
dexamethasone, we assume that a concentration of 10ng/mL dabigatran could be achieved.
In this study, we investigated whether dabigatran reaches potentially relevant levels in the 
vitreous and subretinal fluid after oral administration of a single dose of 220 mg.
201749 proefschrift Verena Mulder_new_2.indd   29 09-02-18   12:44
30
CHAPTE R 2.1
METHODS
This study was approved by the Medical Ethical Committee of the Erasmus Medical Center 
(Rotterdam, The Netherlands), and was registered on www.trialregister.nl (NTR4825). The 
research followed the tenets of the Declaration of Helsinki and all patients signed informed 
consent.
POPULATION 
For this study, we included twenty-eight patients between the age of 18 and 75 years with 
a rhegmatogenous retinal detachment. Twelve patients who were eligible for scleral 
buckling surgery and sixteen patients undergoing vitrectomy. Patients using anti-coagulant 
drugs and drugs that are known to increase the risk of bleeding (e.g. NSAIDs, SSRIs, and 
corticosteroids) were excluded. Other exclusion criteria were a history of stomach ulcer 
or bleeding, creatinine clearance < 50 mL/min and elevated liver enzymes (ASAT, ALAT, 
gamma-GT)  > 2 upper limit of normal. 
INTERVENTION 
Patients received 220 mg of dabigatran etexilate (Pradaxa®) administered as two capsules 
of 110mg with a glass of water on the morning prior to surgery, supervised by the study 
coordinator. The time between intake and surgery was varied between 2 and 8 hours to 
obtain a population-based pharmacokinetic profile. However, exact randomization of the time 
intervals was not possible, because operation schedules are subject to last-minute changes. 
SAMPLE TAKING
Undiluted vitreous (1-1.5 ml) was obtained at the start of vitrectomy, before opening the 
infusion line. During scleral buckle surgery, undiluted subretinal fluid was obtained by 
drainage through a 23 gauge needle mounted on 2 ml syringe without a plunger.10 Vitreous 
and subretinal fluid were immediately injected into Eppendorf vials and stored at –80 ºC. 
A blood sample was collected prior to or at the end of surgery in 0.105 mol/L sodium citrate 
solution. To isolate platelet poor plasma (PPP), the sample was centrifuged for 10 minutes 
at 2500 g/ 4⁰C and stored at -80ºC.
ANALYSIS
Blank control and blinded study samples were sent to Boehringer Ingelheim (Biberach, 
Germany) for analysis. The concentration of dabigatran was measured with liquid 
chromatography - tandem mass spectrometry (LC-MS/MS) according to its validated 
method using the Sciex API 3000 (PerkinElmer, Boston) system.12 The samples were 
injected onto a precolumn and subsequently transferred to an HPLC column (purospher 
RP-18 E analytical column [60 × 2 mm, 5 µm]). MS measurements were performed in the 
positive ionisation mode with [13C6]-labeled BIBR 953 ZW as the internal standard. Monitored 
ions were 472.2  289.5 (dabigatran) and 478.2  295.6 (internal standard). The lower 
limit of quantification (QL) was 1.73 ng/mL. 
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Thrombin inhibiting activity was measured as diluted thrombin time using the Hemoclot 
assay which had a detection limit of 30 ng/mL.13
RESULTS
Forty-four patients were asked to participate. One patient was excluded because of recent 
stomach complaints, six patients were excluded due to abnormal lab results according to 
exclusion criteria and nine patients refrained from participation. Written informed consent 
was obtained from all participants. We included twelve patients in the scleral buckle group 
and sixteen patients in the vitrectomy group. For four patients the surgeon changed the 
initially planned scleral/buckle procedure to vitrectomy right before surgery, hence the 
larger vitrectomy group. Patient characteristics are shown in Table 1.
In addition, we analysed the vitreous fluid of a non-study patient who was on dabigatran 
therapy – 220 mg twice daily – for atrial fibrillation. This patient had a recurrent retinal 
detachment due to a missed break after a previous vitrectomy with gas tamponade for a 
rhegmatogenous retinal detachment. 
Patients were followed up at day 1 and approximately two and six weeks after surgery. 
Dabigatran etexilate was well tolerated by all patients. None of the patients reported any 
side effects and we did not see excessive bleeding during or after surgery. Due to 
redetachment – considered unrelated to the treatment with dabigatran – four patients 
needed additional surgery. Three reoperations in the buckle group were due to insufficiently 
closed retinal breaks and one reoperation in the vitrectomy group was due to PVR.
Table 1. Patient characteristics
Scleral/Buckle (n=12) Vitrectomy (n=16)
Age (yr.)     
median (range) 60 (44 - 69) 62 (48 -71)
Weight (kg)     
median (range) 84 (60 -110) 84 (63 -115)
Gender     
male, n (%) 8 (66) 14 (88)
Body mass index     
 mean (SD*) 26 (± 4.4) 27 (± 3.6)
Creatinine clearance (mL/min)     
median, range 93 (67 -148) 91 (50 -155)
Anaesthesia     
General, n 11 15
Local, n 1 1
Extent of detachment     
1 quadrant (n, %) 4 (33) 6 (38)
2 quadrants 6 (50) 7 (44)
3 quadrants 2 (17) 3 (19)
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DABIGATRAN CONCENTRATION IN VITREOUS AND SUBRETINAL FLUID
Figure 1 shows the semi-logarithmic concentration-time curve of the measured dabigatran 
concentrations by LC-MS/MS. Samples that were below QL are shown as [QL/2]. The 
dabigatran concentration in SRF between 2 and 9 hours after administration ranged from 
below QL to 8.5 ng/mL (mean 4.3ng/mL; n=11). The concentration in vitreous was lower 
and varied between below QL and 3.8 ng/mL (mean 1.9ng/mL; n=15). The vitreous 
concentration of dabigatran in the additional patient on dabigatran therapy was 25.8 ng/mL 
(t = 5 hours after the last dose, data not shown in figure). One SRF value was considered 
an outlier (t = 11hr, 22.4ng/mL).
Figure 2A displays median dabigatran concentrations and the upper and lower limits of 
measurements in four time windows; around 2, 4, 6 and 8 hours. The median concentration 
in SRF showed a peak around 3-5 hours of approximately 8 ng/mL. For vitreous the peak 
seemed to be outside our sampling window.  
DABIGATRAN CONCENTRATION IN PLASMA
Plasma concentrations between 2 and 9 hours after oral administration ranged from 15 ng/
mL to 225 ng/mL (mean 71.3ng/mL; n=25) (Figure 1). Figure 2B shows the median and 
the upper and lower limits of these values in five time windows. The peak concentration 
of approximately 80 ng/mL was reached 1-3 hours after oral administration. The blood 
samples of two patients were unmeasurable due to strong haemolysis; one sample was 
considered an outlier (t = 11hr, 71.6ng/mL). 
Figure 1. Semi-logarithmic concentration-time curve of dabigatran. The squares represent the concentrations 
found in vitreous and in subretinal fluid (SRF). The triangles are their respective plasma concentrations. The 
quantification limit was 1.73 ng/mL. BQL values are shown as [QL / 2].
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DILUTED THROMBIN TIME (DTT)
Anti-thrombin measurements with the standard diluted thrombin time in vitreous and SRF 
were not reliable due to concentrations below the quantification limit of 30-50 ng/mL 
dabigatran. Unfortunately, also the measurements in plasma were not reliable. Partly this 
could be explained by the assay that was used. Re-measurement of the samples with 
different diluted thrombin time kits (Technoclot, Hemosil) showed values closer to the 
LC-MS/MS (gold standard) values (data not shown). 
CORRELATION BETWEEN PLASMA AND OCULAR LEVELS
Although time between ocular fluid sampling and blood sampling varied (26 ± 19 minutes; 
mean ± SD), evaluation of the plasma levels versus the SRF and vitreous levels showed 
that there was a significant relationship between SRF levels and plasma levels (rs = .68, p 
= 0.014); the levels in vitreous fluid showed no such relationship (rs = .20, p = 0.48). 
Figure 2. (A) Median concentrations of dabigatran in vitreous and subretinal fluid (SRF) in different time 
windows. One SRF value was excluded in this graph 22.35ng/mL, 11 hours after intake. (B) Median plasma 
concentrations of dabigatran. One plasma value was excluded in this graph 71.61ng/mL, 11 hours after intake. 
Whiskers represent upper and lower limit of measurements.
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DISCUSSION
The results of the current study demonstrate that a single oral administration of 220mg 
dabigatran etexilate leads to measurable levels of dabigatran in subretinal fluid and vitreous. 
As expected, the dabigatran levels in the eye were significantly lower than in plasma. Based 
on analogy with dexamethasone, we expected that a vitreous concentration of 10ng/mL 
could be achieved, especially because of the assumed partially disrupted blood-retinal barrier. 
In reality, we found concentrations in the range of 2 ng/mL in vitreous. Concentrations in the 
subretinal fluid were somewhat higher (up to 8 ng/mL), possibly due to the closer proximity 
to the choroidal and retinal vessels. This discrepancy between expected and actual values 
might be a result of the difference in lipophilicity between dexamethasone and dabigatran.  
Of a single oral administration of moxifloxacin - an antibiotic with a similar molecular weight 
as dabigatran - only 6.8% of the plasma concentration was found in vitreous (t=±2 hours).14 
Two administrations of the same dose increased the vitreous concentration to 37.5% of 
the plasma concentration (t=3-4 hours).15 Repeated dosing of the oral antiviral drugs 
famciclovir and valacyclovir (prodrugs of penciclovir and acyclovir with comparable 
lipophilicity as dabigatran) led to vitreous concentrations of 27% and 23% of the plasma 
concentration, respectively, in patients with a normal blood-retinal barrier.16, 17 This shows 
that repeated dosing leads to higher intraocular drug levels. 
Extrapolating the above information renders it very likely that repeated dosing of dabigatran 
also leads to higher concentrations. This is supported by the higher levels we found in the 
previously mentioned non-study patient on regular dabigatran intake. Five hours after the 
last dose we found an approximately ten times higher concentration in vitreous (25.8 ng/
mL) than in study patients, despite a similar plasma concentration (52.5 ng/mL). It should 
be noted that this was not a primary vitrectomy. The fluid filling the vitreous cavity after 
vitrectomy might have been less viscous and less resistant to diffusion than vitreous. This 
is a possible mechanism that also leads to higher concentrations through faster diffusion.18
There is little knowledge about pharmacokinetic profiles in vitreous and subretinal fluid. 
Maximum drug concentrations in vitreous are likely to occur later than in plasma. In the 
study of Weijtens et al., the maximum concentration (Cmax) in vitreous and subretinal fluid 
was reached 5 and 4 hours after the Cmax in serum, respectively.10 Therefore, we varied 
the time of intake among patients between 2 and 8 hours prior to surgery to obtain a 
population-based pharmacokinetic profile. Not uncommon for a single dose administration, 
we found a large variability in plasma between individuals. Possibly, this was due to 
predominantly general anaesthesia and its associated need for an empty stomach, which 
may result in an unpredictable absorption.19 Also the concomitant use of a proton-pump 
inhibitor (PPI) – although shown not to interfere with clinical efficacy –  was shown to cause 
variability, a lower Cmax and a 30% lower overall absorption.
19, 20 However, this appeared 
not to be a strong modifier, as the five patients in this study that used a PPI had among 
the highest plasma concentrations. The maximum concentration in SRF appeared around 
the same time as in plasma. The concentration peak in vitreous fluid seemed to lie outside 
our sampling window.  
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To define whether the concentrations we found are therapeutically relevant we calculated 
the required concentration to inhibit 50 and 80% of thrombin activity. Bastiaans et al 
reported a thrombin activity in vitreous of PVR patients of approximately 39 mU/mL (0.56 
nM).2 With the reported inhibition constant (Ki) for dabigatran being 4.5 nM, we calculated 
that the concentration required to inhibit 50% and 80% of this thrombin activity is 
approximately 2 and 9ng/mL, respectively.21 These concentrations are exactly in the range 
of concentrations measured in this study, but as PVR has a protracted course it is unlikely 
that the thrombin concentration has a static value. It is still unclear whether thrombin is 
supplied from the blood stream or also produced locally by the proliferated RPE cells. It is 
important to elucidate these mechanisms in order to determine if a high enough 
concentration is reached to competitively inhibit thrombin. 
In patients with a retinal detachment due to PVR, contractile periretinal membranes are 
formed that cause re-detachment or prevent reattachment. These membranes are formed 
during an inflammatory and fibrotic process, involving cytokines, growth factors and cells, 
such as RPE cells. To prevent or treat PVR in patients, anti-inflammatory (steroids) and 
cell-cycle inhibitors (daunorubicin, retinoic acid, and 5-FU) have been used, the latter 
particularly to decrease RPE cell proliferation.7, 8, 22-25 Heparin has also been used, without 
a clearly described rationale, but likely to prevent fibrin deposition or to bind growth factors.
Apart from prednisone, colchicine and retinoic acid, administration of all agents occurred 
during surgery. Due to the protracted course of PVR, a single intravitreal injection or 1-hour 
drug exposure during vitrectomy is unlikely to be effective in prevention or modulation. To 
obtain effective drug levels over a sustained period of time repeated administration is 
necessary. The most efficient way remains local delivery by intravitreal injection, but these 
are not only inconvenient for the patient, they also pose a large risk of infection. 
Dabigatran has a plausible mode of action to modulate PVR and is a relatively safe and 
patient-friendly drug for repeated administration. Its use has become even safer since the 
availability of an antagonist in case of excessive bleeding.26 Nevertheless, all drugs have 
potential side effects. Therefore, it remains important to select those patients most at risk 
of developing PVR. 
In conclusion, we have demonstrated that oral intake of dabigatran, a candidate drug to 
modulate PVR, results in potentially relevant intraocular concentrations. We suggest that 
repeated dosing may lead to higher concentrations, but this should be further explored.
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INTRODUCTION
The oral thrombin inhibitor dabigatran (Pradaxa®) has been shown to be detectable in the 
vitreous and subretinal fluid after a single oral administration of 220mg.1 The maximum 
concentrations that were found were 8.5ng/ml in subretinal fluid and 3.8ng/ml in vitreous. 
An unexpected finding in this study was the 10 times higher vitreous concentration of a 
non-study patient, who used 150mg dabigatran twice daily for atrial fibrillation. This finding 
in combination with the observation that the median vitreous concentration was highest 
at our last time point and thus possibly still increasing, led to the hypothesis that repeated 
administration of dabigatran might lead to higher intraocular levels. Therefore, we tested 
this hypothesis in patients on standard dabigatran therapy who were admitted to the 
Rotterdam Eye Hospital for retinal surgery.
METHODS AND RESULTS 
We were able to include one male and two female patients, who were being treated with 
standard twice daily dosages of dabigatran (see table 1). One patient underwent surgery 
for a dropped nucleus after cataract surgery and two patients for a macular hole. One of 
these patients had a persistent macular hole and underwent repeat surgery after 5.5 weeks 
during which we collected a second sample. The collection of undiluted vitreous samples 
and analysis with LC-MS/MS were the same as described in our previous study.1 
Table 1. Patient characteristics and results
Patient 1 Patient 2 Patient 3
Age 89 yr 81 yr 71 yr
Gender Female Male Female
Weight 49 kg 90 kg 65 kg
Body mass index 18 29 21
Anaesthesia Local Local General
Reason for surgery dropped nucleus macular hole macular hole
2. persistent macular 
hole
Dosage of dabigatran 2 x 110mg 2 x 110mg 2 x 150mg
Concentration in vitreous 
(time after last intake)
10.1ng/ml (4.5hr) 5.6 ng/ml (6.0hr) 1. 6.0ng/ml (3.6hr)
2. 19.5 ng/ml (3.5hr)
Concentration in plasma 
(time after last intake)
- 95.8 ng/ml (7.3hr) 1. 159.1 ng/ml (5.0hr)
2. 100.4 ng/ml (3.3hr)
Concomitant medication bumetanide, metoprolol, 
perindopril, isosorbide 
mononitrate, ranitidine, 
spironolactone 
valsartan, 
hydrochlorthiazide
chlorthalidone, 
desloratadine, fluticasone, 
digoxin, pravastatin
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DISCUSSION
Due to the relative rarity of patients on dabigatran therapy undergoing vitrectomy, we were 
able to include only three unique patients in one year of which one on two separate 
occasions. These were not patients with a rhegmatogenous retinal detachment (RRD) – like 
the previous study – but patients with a macular hole and a complication after cataract 
surgery. This difference in patient population might have influenced the measured vitreous 
concentrations. In contrast to patients with a macular hole, we assume that patients with 
RRD have a partially disrupted blood-retinal barrier which contributes to the influx of 
dabigatran in the vitreous. Therefore, these results show that even with an intact blood-
retinal barrier dabigatran is able to penetrate the vitreous as long as there is sufficient 
supply (i.e. repeated administration). 
In addition, the presence of formed vitreous seemed to influence the concentration in the 
vitreous cavity. Patient 3 underwent two consecutive vitrectomy procedures in which we 
both collected vitreous respectively vitreous cavity fluid samples. The collection time was 
in both cases 3.5 hours after the last dose, but the concentration of dabigatran in the second 
sample was much higher than in the first one (6.0 ng/ml vs. 19.5 ng/ml).  A possible 
explanation for this result is the lower viscosity of aqueous humour filling the vitreous 
cavity after the first vitrectomy.2, 3 As dabigatran is a hydrophilic compound, lower viscosity 
possibly results in higher diffusion in this medium than in vitreous.3 The same mechanism 
might have contributed to the high concentration we found in our previous study (25.8 ng/
ml). 
In conclusion, we have demonstrated that repeated use of the oral thrombin inhibitor 
dabigatran leads to higher vitreous levels of dabigatran than a single administration, even 
in patients with a supposedly intact blood-retinal barrier. This result increases the potential 
of dabigatran as a possible therapeutic agent in the modulation of PVR.   
Table 1. Patient characteristics and results
Patient 1 Patient 2 Patient 3
Age 89 yr 81 yr 71 yr
Gender Female Male Female
Weight 49 kg 90 kg 65 kg
Body mass index 18 29 21
Anaesthesia Local Local General
Reason for surgery dropped nucleus macular hole macular hole
2. persistent macular 
hole
Dosage of dabigatran 2 x 110mg 2 x 110mg 2 x 150mg
Concentration in vitreous 
(time after last intake)
10.1ng/ml (4.5hr) 5.6 ng/ml (6.0hr) 1. 6.0ng/ml (3.6hr)
2. 19.5 ng/ml (3.5hr)
Concentration in plasma 
(time after last intake)
- 95.8 ng/ml (7.3hr) 1. 159.1 ng/ml (5.0hr)
2. 100.4 ng/ml (3.3hr)
Concomitant medication bumetanide, metoprolol, 
perindopril, isosorbide 
mononitrate, ranitidine, 
spironolactone 
valsartan, 
hydrochlorthiazide
chlorthalidone, 
desloratadine, fluticasone, 
digoxin, pravastatin
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ABSTRACT
PURPOSE 
Proliferative vitreoretinopathy (PVR) is a vitreoretinal disorder in which retinal pigment 
epithelial (RPE) cell activation contributes to both formation of fibrotic retinal membranes 
and inflammation. Vitreous of PVR patients contains increased thrombin activity which 
induces pro-fibrotic and pro-inflammatory  programs in RPE cells. Inhibition of intravitreal 
thrombin activity may thus represent a therapeutic option for PVR. In this study, we 
examined the capacity of the clinically available direct thrombin inhibitor dabigatran to inhibit 
thrombin activity in vitreous fluids.
METHODS 
ARPE-19 cells were cultured with 1) thrombin, 2) vitreous without thrombin activity and 3) 
vitreous with elevated thrombin activity (PVR samples and thrombin spiked vitreous) either 
in the presence or absence of dabigatran (range: 10-5 - 10-7 M). Subsequently, CCL2, CXCL8, 
GM-CSF, IL6, and PDGF-B mRNA expression levels were determined by RQ-PCR and 
protein levels of 27 cytokines, chemokines and growth factors were detected in culture 
supernatants using a multiplex approach. In addition, the capacity of vitreous fluids obtained 
from patients after oral dabigatran intake was tested in an in vitro thrombin activity assay. 
RESULTS 
Thrombin and vitreous fluids containing thrombin activity induced CCL2, CXCL8, GM-CSF, 
IL-6 and PDGF-BB expression by ARPE-19 cells, which was inhibited by dabigatran. In 
addition, dabigatran that reached the vitreous after repeated oral intake did inhibit thrombin 
activity in the in vitro activity assay.
CONCLUSION 
PVR is associated with increased intravitreal thrombin activity that activates pro-fibrotic 
and pro-inflammatory pathways in RPE cells. Our findings provide evidence that this 
activation pathway can potentially be inhibited by dabigatran. 
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INTRODUCTION
Thrombin is a key serine protease of blood coagulation that converts soluble fibrinogen 
into insoluble fibrin.1 In addition to its role in coagulation, thrombin induces cellular 
responses that have important roles in inflammation and tissue repair, but also contribute 
to the development of fibrosis.2-4 Thrombin, for instance, stimulates the production of 
inflammatory mediators by several cell types, promotes chemotaxis of inflammatory cells, 
stimulates the proliferation of fibroblasts and smooth muscle cells, and induces 
myofibroblast differentiation and the production of extracellular matrix (ECM) components 
such as collagen.5 These cellular responses to thrombin are mostly mediated via the G 
protein-coupled protease-activated receptor (PAR)-1.6    
Proliferative vitreoretinopathy (PVR) is a complication of retinal detachment – caused by a 
retinal tear (rhegmatogenous retinal detachment (RRD)) or trauma – which is characterized 
by the formation of subretinal, intraretinal, and/or epiretinal fibrotic membranes, as well as 
an inflammatory component.7, 8  Retinal pigment epithelial (RPE) cells dispersed during 
retinal detachment are important contributors to PVR pathogenesis as they dedifferentiate 
into collagen-producing myofibroblasts, which is a key event in the development of the 
contractile fibrotic membranes.7 Moreover, the activated RPE cells produce cytokines and 
chemokines that recruit and activate immune cells.8 Although these pathobiological 
processes are well recognized to contribute to PVR, medical treatment options are limited 
so far, and treatment mostly still depends on (recurrent) surgical intervention.7
Activation of the coagulation cascade, as evidenced by intraocular fibrin deposition and 
higher intravitreal thrombin activity, occurs in PVR and likely contributes to both retinal 
fibrotic membrane formation and inflammation.9-11 Previously, we demonstrated that 
thrombin stimulated dedifferentiation of RPE cells into α-smooth-muscle-actin-expressing 
contractile, collagen-producing myofibroblasts. This involved production of the profibrotic 
mediator platelet-derived growth factor (PDGF)-BB and subsequent autocrine activation of 
the PDGF-receptor.9, 12 In line with this, we also showed that thrombin activity in vitreous 
from patients with PVR is a main contributing component of vitreous-induced production 
of PDGF-BB by RPE.9 
Elevated thrombin activity in vitreous of patients with PVR was also identified as an 
important stimulator of the production of pro-inflammatory mediators such as C-C motif 
chemokine ligand (CCL)2, C-X-C motif chemokine ligand (CXCL)8, granulocyte-macrophage-
colony-stimulating factor (GM-CSF) and interleukin (IL)-6 by RPE. CCL2, CXCL8, GM-CSF 
and IL-6 are potent chemoattractants and activators of immune cells such as monocytes, 
macrophages, neutrophils and B-lymphocytes which have been identified in PVR 
membranes and vitreous. GM-CSF also stimulates differentiation of monocytes into 
macrophages.7,8,13-17 These immune cells, especially monocytes/macrophages, are 
considered an important source of pro-fibrotic mediators in PVR, including PDGF and 
transforming growth factor (TGF)-β which are elevated in vitreous and membranes of patient 
with PVR.7, 8, 18 
201749 proefschrift Verena Mulder_new_2.indd   47 09-02-18   12:44
48
CHAPTE R 2.3
Altogether, this data points to an important role for thrombin in stimulating and prolonging 
pro-fibrotic and pro-inflammatory responses by RPE in PVR. Thrombin may, therefore, 
represent an attractive treatment target for this complication. This consideration, however, 
is not new. Peroperative intravitreal low-molecular-weight heparin was used in 3 randomized 
controlled trials on PVR modulation, with an inhibiting effect only seen in patients at high 
risk of developing PVR.19-21 As PVR is a protracted process, a more prolonged treatment 
by an oral drug may be more appropriate.
Dabigatran-etexilate is a small molecule oral prodrug that is hydrolysed to its active 
compound dabigatran. Dabigatran is a selective, competitive and reversible direct thrombin 
inhibitor (DTI) that binds to the active site of the thrombin molecule, thereby blocking the 
interaction between thrombin and its substrates.22 Dabigatran prevents cleavage of 
fibrinogen by thrombin (at particular Arg-Gly bonds) thereby preventing the formation of 
fibrin and thus negatively affects clotting. Dabigatran also inhibits thrombin-induced 
cleavage of PAR-1 at the peptide bond between residues Arg-41 and Ser-42, thereby 
preventing cells from being activated.23, 24 Recently, Mulder et al demonstrated that 
dabigatran is able to reach the vitreous and subretinal fluid after oral intake, making 
dabigatran an interesting drug candidate to modulate PVR development.25, 26 Together these 
data suggest that dabigatran may be considered as a potential drug for the treatment of 
disorders associated with elevated intravitreal thrombin activity, including PVR. Therefore 
the aim of the present study was to investigate whether dabigatran exhibits the capacity 
to inhibit thrombin activity within the vitreous environment.
MATERIALS AND METHODS
VITREOUS FLUIDS
Vitreous fluid samples were selected from our previous studies. 9, 25 Vitreous fluid samples 
without thrombin activity were collected from patients during their primary vitrectomy 
procedure for RRD, who had not developed PVR afterwards (n=5). Vitreous fluid samples 
with thrombin activity were collected from patients with established PVR (mean thrombin 
activity = 56.19 ± 83.62 mU/ml) (n = 5). In these vitreous fluid samples, thrombin activity 
was determined by using the thrombin-specific substrate Tos-Gly-Pro-Arg-pNA (Sigma-
Aldrich, St. Louis, MO) as described previously.9 
Vitreous fluid samples containing dabigatran were collected from patients during their 
primary vitrectomy procedure for RRD which received dabigatran before surgery (mean 
measured dabigatran = 3.23 ± 6.89 ng/ml) (n = 13). 
All subjects gave their consent for the use of rest material for research; storage and use 
of the vitreous for further studies were according to the guidelines of the Medical Ethics 
Committee of the Erasmus MC, University Medical Center, Rotterdam and were performed 
in accordance with guidelines established by the Declaration of Helsinki.
201749 proefschrift Verena Mulder_new_2.indd   48 09-02-18   12:44
49
DAB IGATRAN I N H I B ITS I NTRAVITR EAL TH ROMB I N ACTIVITY
2.3
CELL CULTURES
The human retinal pigment epithelial cell line ARPE-19 was obtained from American Type 
Culture Collection (ATCC; Manassas, VA, US). ARPE-19 cells were cultured in RPE 
medium (Dulbecco’s modified Eagle’s medium /F-12 (HyClone, Logan, UT, US)), containing 
10% heat-inactivated fetal calf serum (FCS) and penicillin/streptomycin (all from 
BioWhittaker, Verviers, Belgium)) and were between passage 23-30 when used for 
experiments. ARPE-19 cells were analysed by short tandem repeat (STR) analysis (DSMZ, 
Braunschweig, Germany) for cell line authentication and were mycoplasma free. ARPE-
19 cells were maintained under standard cell culture conditions at 37 oC in humidified air 
with 5% CO2.
DABIGATRAN TITRATION
ARPE-19 cells were seeded at a density of 3 x 105 cells/well in RPE medium containing 
10% FCS in 12-well plates and were allowed to adhere overnight. Subsequently, the 
medium was refreshed twice a week till the cells were grown 100% confluent. Prior to 
stimulation, the cells were serum starved in RPE medium containing 1% FCS for 24 hours, 
followed by an additional 24 hours in serum-free RPE medium. Hereafter, cells were pre-
incubated with fresh serum-free RPE medium with or without active dabigatran for 60 
minutes (BIBR 953, range: 10-5-10-7M: kindly provided by Boehringer Ingelheim Pharma 
GmbH & Co. KG (Ingelheim am Rhein, Germany)). Subsequently, thrombin (Calbiochem, 
La Jolla, CA) was added to a concentration of 5 U/ml (concentration based on previous 
studies 9, 12, 27) or cells remained unstimulated for a period of 2 hours. Hereafter cells were 
harvested for RNA isolation. The dabigatran concentrations that were used were non-toxic 
to ARPE-19 cells as was determined by lactate dehydrogenase (LDH) release (Roche, 
Mannheim, Germany) and microscopic appearance of the cells. 
THE ABILITY OF DABIGATRAN TO INHIBIT PVR-VITREOUS-INDUCED 
CYTOKINE, CHEMOKINE AND GROWTH FACTOR EXPRESSION LEVELS
ARPE-19 cells were seeded in 12-well plates at a density of 3 x 105 cells/well in RPE 
medium containing 10% FCS and allowed to adhere overnight. Subsequently, the medium 
was refreshed twice a week till the cells were grown 100% confluent. Prior to stimulation, 
the cells were serum starved in RPE medium containing 1% FCS for 24 hours followed by 
an additional 24 hours in serum-free RPE medium. Hereafter, cells were pre-incubated with 
serum-free RPE medium with or without 10-5 M dabigatran or 7.5 U/ml hirudin for 60 
minutes and subsequently stimulated for 2 hours with serum-free medium containing 1/8 
diluted vitreous (dilution based on previous study 9) with or without 10-5 M dabigatran or 
7.5 U/ml hirudin. Hereafter cells were harvested for RNA isolation. 
MESSENGER RNA EXPRESSION ANALYSIS BY REAL-TIME QUANTITATIVE PCR
RNA was isolated using a GenEluteTM Mammalian Total RNA Miniprep Kit (Sigma-Aldrich) 
and reverse transcribed into cDNA.9 Transcript levels of CCL2, CXCL8, GM-CSF, IL6 and 
PDGF-B mRNA were determined by real-time quantitative (RQ)-PCR (7700 PCR system; 
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Applied Biosystems [ABI], Foster City, CA, US) using primer and probe combinations as 
previously described.9 Expression levels of the analysed gene transcripts were normalized 
to the control gene ABL (Abelson).9 
MULTIPLEX DETECTION OF THROMBIN AND VITREOUS-INDUCED CYTOKINE, 
CHEMOKINE AND GROWTH FACTOR EXPRESSION 
ARPE-19 cells were seeded in 12-well plates at a density of 3 x 105 cells/well in RPE 
medium containing 10% FCS and allowed to adhere overnight. Subsequently, the medium 
was refreshed twice a week till the cells were grown 100% confluent. Prior to stimulation, 
the cells were serum starved in RPE medium containing 1% FCS for 24 hours followed by 
an additional 24 hours in serum-free RPE medium without FCS. Hereafter cells were pre-
incubated with fresh serum-free RPE medium with or without or 10-5 M dabigatran or 7.5 
U/ml hirudin (Sigma, St Louis, MO, US) for 60 minutes. Subsequently, the cells were 
stimulated with serum-free medium containing 1/8 diluted thrombin-free vitreous with or 
without 5 U/ml thrombin, with or without 10-5 M dabigatran or 7.5 U/ml hirudin for 24 hours. 
As a control, cells were stimulated in serum-free medium with or without 5 U/ml thrombin 
for 24 hours. Following the stimulation period of 24 hours, culture supernatants were 
harvested and analysed with a Bio-Plex Pro™ Human Cytokine, Chemokine, and Growth 
Factor Assay (Bio-Rad, Hercules, CA, US) for simultaneous detection of the following 
cytokines, chemokines and growth factors: basic fibroblast growth factor (FGFb), Eotaxin, 
CCL2, CCL3, CCL4, CCL5, CXCL8, CXCL10, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, 
IL-10, IL-12 (p70), IL-13, IL-15, IL-17, G-CSF, GM-CSF, interferon (IFN)γ, PDGF-BB, tumour 
necrosis factor (TNF)-α, vascular endothelial growth factor (VEGF)-A (see supplemental 
table 1 for the detection limits). The assay was performed according manufacturer’s 
instructions. Because CXCL8 levels in a few culture supernatants exceeded the upper 
detection limit of the assay all culture supernatants were re-analysed for CXCL8 by ELISA 
(Invitrogen) according manufacturer’s instructions.
DABIGATRAN ACTIVITY IN VITREOUS FLUIDS 
In previous studies, dabigatran was detected in the vitreous of patients which had either 
received a single oral dosage 2-9 hours before vitrectomy or were being treated 
therapeutically with dabigatran.25, 28 In this study, we measured the activity of dabigatran 
in those vitreous samples collected during vitrectomy, by using a thrombin-specific 
substrate as described in our previous study.9 In short, 50 µl vitreous fluid containing 
dabigatran was diluted in a 96-well microtiter plate with 50 µl of a 1 mM solution of the 
thrombin specific substrate Chromozym TH (Sigma) dissolved in 1.5 mM HCl. Thereafter, 
5 µl Tris-buffered saline (TBS) pH 8.3 or TBS containing 1 U/ml thrombin was added to each 
reaction. Vitreous fluids without dabigatran were taken along as controls. A thrombin 
standard curve ranging from 50 - 0.78 mU/ml was prepared in TBS or TBS containing 0.1 
U/ml hirudin. The reaction was performed in an incubator at 37 oC. The optical density (OD) 
was measured at 405 nm after 4 hours. Thrombin activity in vitreous fluid was quantified 
based on the difference in OD between vitreous fluid with and without dabigatran, and the 
reference curve, and was expressed as mU/ml.
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STATISTICAL ANALYSIS
Data were analysed using the Kruskal-Wallis (One-way ANOVA) test followed by the Mann-
Whitney U test when applicable. A P-value < 0.05 was considered significant. 
RESULTS
THE CONCENTRATION-DEPENDENT EFFECT OF DABIGATRAN ON THROMBIN-
INDUCED CYTOKINE, CHEMOKINE AND GROWTH FACTOR EXPRESSION
Thrombin significantly (P < 0.05) induced CCL2, CXCL8, GM-CSF, IL6, and PDGF-B mRNA 
expression levels in ARPE-19 (Figure 1). This stimulatory effect of thrombin was dose-
dependently inhibited by dabigatran for all genes, becoming significant (P < 0.05) at a 
concentration of 10-5 M which is approximately 4.7 µg/ml (Figure 1). Dabigatran without 
the addition of thrombin did not induce or inhibit mRNA expression levels of CCL2, CXCL8, 
GM-CSF, IL6 and PDGF-B (Figure 1).  
THE EFFECT OF DABIGATRAN ON VITREOUS-INDUCED CCL2, CXCL8, GM-CSF, 
IL6 AND PDGFB EXPRESSION
Vitreous fluids from RDD patients that lacked detectable thrombin activity did not induce 
CCL2, CXCL8, GM-CSF, IL6 and PDGF-B mRNA expression by ARPE-19 cells nor was this 
affected by dabigatran (Figure 2A). Vitreous fluids from patients with PVR that contained 
thrombin activity clearly induced CCL2, CXCL8, GM-CSF, IL6, and PDGF-B mRNA 
expression by ARPE-19 cells. The addition of dabigatran significantly (P < 0.05) reduced 
the capacity of these PVR vitreous samples to induce CCL2, CXCL8, IL6 and PDGF-B mRNA 
expression by ARPE-19 (Figure 2B).      
Figure 1. ARPE-19 cells were stimulated for 2 hours with thrombin (5 U/ml) or remained unstimulated in the 
absence or presence of dabigatran (range: 10-5 - 10-7 M). CCL2, CXCL8, GM-CSF, IL6 and PDGF-B mRNA 
expression levels were determined by RQ-PCR and normalized against the control gene ABL. Data are 
presented as the mean value from 4 independent experiments ± SEM. Statistical analysis was performed 
with the Kruskal-Wallis (One-way ANOVA) test followed by the Mann-Whitney U test when applicable. P < 
0.05 was considered significant. * = P < 0.05 and ** = P <0.01.
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THE EFFECT OF DABIGATRAN ON THROMBIN-INDUCED CYTOKINE, 
CHEMOKINE AND GROWTH FACTOR PRODUCTION
Thrombin significantly (P < 0.05) induced CCL2, CXCL8, GM-CSF, IL-6 and PDGF-BB protein 
production by ARPE-19 cells in both serum-free medium and vitreous-diluted medium 
(Figure 3). This stimulatory effect of thrombin was inhibited by both hirudin (P < 0.05) and 
dabigatran (P < 0.05) for all. Hirudin and dabigatran alone did not affect CCL2, CXCL8, GM-
CSF, IL-6 and PDGF-BB production (Figure 3). Other cytokines, chemokines and growth 
factors which were upregulated by thrombin in both serum-free medium and vitreous 
diluted medium are IL-9, IL-10, IL-12(p70), FGFb and VEGF-A (supplemental table 1). For 
these factors, the stimulatory effect of thrombin was inhibited by both hirudin and 
dabigatran as well (supplemental table 1). 
INTRAVITREAL DABIGATRAN INHIBITS THROMBIN ACTIVITY
Vitreous fluids from patients which were given dabigatran 2-9 hours before surgery 
contained a concentration of 3.23 ± 6.89 ng/ml dabigatran. Allowing these vitreous fluids 
to inhibit thrombin activity in a thrombin activity assay with a thrombin-specific chromogenic 
substrate, showed hardly any effect of the dabigatran in the vitreous fluid on the thrombin 
activity (Figure 4). However, one vitreous fluid of a patient which has been taken dabigatran 
on a daily basis for a longer time period for atrial fibrillation contained a much higher 
concentration (25.84 ng/ml, undiluted) of dabigatran and inhibited total thrombin activity 
(Figure 4).
Figure 2. ARPE-19 cells were stimulated for 2 hours with (A) 1/8 diluted vitreous without thrombin activity, 
in the absence or presence of dabigatran (10-5 M) or hirudin (7.5 U/ml) or (B) 1/8 diluted vitreous with thrombin 
activity, in the absence or presence of dabigatran (10-5 M)  or hirudin (7.5 U/ml). CCL2, CXCL8, GM-CSF, IL6 
and PDGF-B mRNA expression levels were determined by RQ-PCR and normalized against the control gene 
ABL. Data are presented as the mean value from 4 independent experiments ± SEM. Statistical analysis 
was performed with the Kruskal-Wallis (One-way ANOVA) test followed by the Mann-Whitney U test when 
applicable. P < 0.05 was considered significant. * = P < 0.05 and ** = P < 0.01.
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Figure 3. ARPE-19 cells were stimulated with thrombin (5 U/ml) in serum free medium (light grey bars) or 
1/8 diluted vitreous fluids in medium (dark grey bars) in the absence or presence of dabigatran (10-5 M) or 
hirudin (7.5 U/ml) for 24 hours. Culture supernatants were analysed by a Bio-Plex Pro™ Human Cytokine, 
Chemokine, and Growth Factor Assay; allowing the detection of 27 cytokines, chemokines and growth factors 
simultaneously. CCL2, CXCL8, GM-CSF, IL-6 and PDGF-BB data are presented as the mean value from 6 
individual vitreous fluids per group ± SEM and from 4 individual serum free and vitreous free medium samples 
per group ± SEM. Statistical analysis was performed with the Kruskal-Wallis (One-way ANOVA) test followed 
by the Mann-Whitney U test when applicable. P < 0.05 was considered significant. 
* = P < 0.05,  ** = P < 0.01 and ns = no significant difference.
Figure 4. Dabigatran activity in vitreous fluids (2-9 hours after oral intake) was determined with a thrombin 
activity assay by using the thrombin-specific chromogenic substrate Chromozym TH in the absence and 
presence of thrombin (50 mU/ml). Black diamonds indicate vitreous fluids with dabigatran concentrations > 
detection limit 1.73 ng/ml and dark grey crosses indicate vitreous fluids with dabigatran concentrations < 
detection limit 1.73 ng/ml as previously determined.1 Light grey circles indicate vitreous fluids without 
dabigatran.
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DISCUSSION 
There is accumulating evidence that elevated intravitreal thrombin activity is involved in 
the pathogenesis of PVR and that its contribution goes beyond fibrin formation. In PVR, 
thrombin activates PAR-1 signalling in RPE cells which results in the production of numerous 
cytokines, chemokines and growth factors including the proinflammatory cytokines CCL2, 
CXCL8, GM-CSF, IL-6 and the pro-fibrotic mediator PDGF-BB. Inhibition of thrombin may 
thus represent an attractive therapeutic option for PVR treatment. Two recent studies by 
Mulder et al demonstrated that the clinically available DTI dabigatran can be detected in 
vitreous fluid and subretinal fluid of patients 25, and in higher concentration after repeated 
dosing28. The question remains whether dabigatran is able to prevent thrombin from 
activating RPE cells in a vitreous enriched environment which is rich in salts, sugars, 
collagens, hyaluronic acid and a wide array of proteins which may affect dabigatran’s 
efficiency to inhibit thrombin activity.29-31
To answer our research question we conducted four experiments. First, we tested the 
ability of dabigatran to prevent the induction of five factors that were previously shown to 
be significantly induced by thrombin (CCL2, CXCL8, GM-CSF, IL6 and PDGF-B) on mRNA 
level (Figure 1). Second, we tested whether dabigatran was also able to prevent the 
induction of these factors in a more realistic environment containing vitreous with 
endogenous thrombin activity (Figure 2). Third, we wanted to confirm whether the effects 
we see on mRNA level also translate into similar effects on protein level (Figure 3). Lastly, 
we tested the thrombin-inhibiting effect of dabigatran present in vitreous after oral 
administration to confirm that this dabigatran (Figure 4) has a comparable thrombin-inhibitory 
effect as the active compound BIBR 953 which was used in the in vitro experiments with 
ARPE-19 cells (Figure 1-3). In this study, we demonstrate that dabigatran etexilate, a 
candidate drug to modulate PVR development, is able to inhibit thrombin-induced expression 
of cytokines, chemokines and growth factors in a vitreous environment. 
For this study, there was little availability of vitreous fluids with increased thrombin activity. 
The available volumes were just sufficient to perform our mRNA experiments, which 
required smaller amounts of the fluids. Therefore vitreous fluids lacking endogenous 
thrombin activity were used for the experiments involving the simultaneous detection of 
27 cytokines, chemokines and growth factors via a multiplex approach. For these 
experiments, when required, these vitreous fluids were spiked with thrombin purified from 
human plasma to resemble PVR vitreous fluids. This may affect expression levels of various 
cytokines, chemokines and growth factors, which is taken into consideration. Furthermore, 
we and others have demonstrated that when studying the thrombin-induced expression 
of cytokines, chemokines and growth factors, ARPE-19 cells and primary RPE respond in 
a similar matter.9, 12, 27, 32-36  Therefore only ARPE-19 cells were used in this study.
Recently we demonstrated that thrombin activity is increased in vitreous from PVR patients 
where it is a major factor contributing to vitreous-induced production of CCL2, CXCL8, 
GM-CSF and IL-6 by ARPE-19 cells.9 Here we demonstrate that dabigatran inhibits the PVR 
vitreous-induced CCL2, CXCL8, GM-CSF and IL6 mRNA expression and thrombin-induced 
CCL2, CXCL8, GM-CSF and IL-6 protein expression in ARPE-19 cells (Figure 2 and 3). The 
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concentration of dabigatran in our first three experiments was approximately 1000x higher 
compared to the concentrations found in the vitreous after oral intake.25 However, these 
high concentrations were required to inhibit thrombin activity in our in vitro experiments 
(Figure 1) and have been demonstrated to be non-toxic to the cells.
Dedifferentiation of RPE cells into contractile extracellular-matrix-synthesizing myofibroblasts 
is a key event in the formation of fibrotic membranes in PVR.7 Thrombin is an important 
driver of this dedifferentiation process which depends on the autocrine release of PDGF-BB 
and subsequent PDGF-receptor activation.27, 37 Here we found that dabigatran inhibits 
thrombin and PVR vitreous-induced expression of PDGF-BB on both mRNA and protein 
level in ARPE-19 cells (Figure 2 and 3), suggesting that dabigatran may prevent thrombin-
induced fibrotic responses in RPE cells. 
In our experiments we used hirudin, a DTI which effectively inhibited thrombin in previous 
studies, as a control for dabigatran. Although the inhibitory effect of hirudin on thrombin 
is irreversible as opposed to dabigatran - a competitive and reversible DTI - the effect on 
cytokines, chemokines and growth factors expression levels were similar.9
Available vitreous fluids containing dabigatran from a previous study by Mulder et al were 
used in a reversed version of a thrombin activity assay.25 This assay has the elegance to 
study the effect of intravitreal dabigatran (that is dabigatran which reached the patients’ 
vitreous fluid hours after oral intake) on thrombin activity. Although our findings do not find 
a strong effect, we find that one of the vitreous fluids, containing 12.92 ng/ml dabigatran 
after dilution, is able to inhibit all thrombin activity provided (Figure 4). This is in agreement 
with the previously reported theoretical minimum concentration range of dabigatran required 
to inhibit the measured thrombin activity in vitreous based on the inhibition constant of 
dabigatran (4.5nM).25, 38 Vitreous fluids without dabigatran, which were taken along as 
controls, had no effect on thrombin activity (light grey circles in Figure 4). However, a few 
samples with concentrations of dabigatran which were reported to be below the detection 
limit, were able to partially inhibit thrombin activity (dark grey crosses in Figure 4).25 In our 
assay we found increased levels of protease activity in these vitreous fluids (data not shown). 
Proteases have been found in vitreous before and may have interfered with this assay.39 
The increased levels of protease activity were, however, restricted to these fluids.
Taken together our data suggest that thrombin inhibition with a DTI such as dabigatran 
may be an interesting therapeutic option in the prevention of PVR development. It should 
however still be taken into account that the use of a compound such as dabigatran, with 
potential side effects including haemorrhages, should be introduced with great 
precaution.40-42
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Supplemental table 1. Bio-Plex Pro™ Human Cytokine, Chemokine, and Growth Factor Assay analysis
culture media culture media + 
thrombin
vitreous vitreous + 
dabigatran
vitreous + hirudin vitreous + 
thrombin
“vitreous + 
thrombin +
dabigatran”
“vitreous + 
thrombin +
hirudin”
LLOQ ULOQ
IL-1β 0.46 ± 0.8 0.84 ± 0.02 0.41 ± 0.02 0.41 ± 0.04 0.34 ± 0.02 1.44 ± 0.07 0.46 ± 0.05 0.40 ± 0.05 3.2 3261
IL-1rα not detectable 81.1 70487
IL-2 not detectable 2.1 17772
IL-4 0.39 ± 0.07 0.91 ± 0.04 0.34 ± 0.02 0.34 ± 0.02 0.27 ± 0.01 1.47 ± 0.07 0.38 ± 0.05 0.33 ± 0.04 2.2 3467
IL-5 not detectable 3.1 7380
IL-6 5.54 ± 1.48 430.39 ± 42.72 20.90 ± 5.39 20.87 ± 5.00 18.03 ± 5.60 1127.75 ± 132.20 23.55 ± 5.52 22.60 ± 8.44 2.3 18880
IL-7 3.98 ± 0.48 5.47 ± 0.16 3.54 ± 0.30 3.96 ± 0.30 3.59 ± 0.39 8.93 ± 0.44 3.97 ± 0.31 3.66 ± 0.44 3.1 6001
IL-8/CXCL8 46.45 ± 5.52 6634.67 ± 1445.81 247.85 ± 51.70 145.86 ± 48.29 103.71 ± 30.21 not detectable 159.14 ± 48.07 115.76 ± 32.89 1.9 26403
IL-9 10.71 ± 1.45 31.95 ± 1.12 9.05 ± 0.94 8.53 ± 0.98 6.70 ± 0.36 40.04 ± 1.29 9.96 ± 2.10 8.09 ± 0.99 2.1 7989
IL-10 13.95 ± 1.50 26.75 ± 0.97 14.64 ± 0.68 15.53 ± 0.95 13.82 ± 0.74 31.95 ± 1.19 16.65 ± 1.29 16.08 ± 1.83 2.2 8840
IL-12 (p70) 75.45 ±  6.18 143.39 ± 3.41 75.69 ± 3.64 79.81 ± 4.20 70.65 ± 3.68 165.47 ± 5.11 82.69 ± 5.93 78.67 ± 5.20 3.3 13099
IL-13 0.57 ± 0.10 0.74 ± 0.03 0.44 ± 0.03 0.46 ± 0.03 0.39 ± 0.03 1.11 ± 0.07 0.49 ± 0.07 0.42 ± 0.03 3.7 3137
IL-15 not detectable 2.1 2799
IL-17 not detectable 4.9 12235
FGFb 152.86 ± 45.33 212.11 ± 34.08 40.62 ± 9.65 49.23 ± 16.60 21.90 ± 1.96 159.56 ± 46.19 101.78 ± 67.76 31.23 ± 5.14 40.9 5824
Eotaxin not detectable 27.2 7581
G-CSF not detectable 2.4 11565
GM-CSF 42.16 ± 4.18 169.83 ± 6.79 24.61 ± 1.86 34.82 ± 4.50 30.05 ± 2.56 219.26 ± 20.68 34.93 ± 4.35 28.88 ± 2.74 63.3 6039
IFNγ not detectable 92.6 52719
IP-10/CXCL10 not detectable not detectable 16.86 ± 4.23 16.99 ± 4.14 15.53 ± 3.68 20.66 ± 5.27 6,03 18.83 ± 6.42 18.8 26867
MCP-1/CCL2 500.92 ± 46.28 1135.27 ± 142.22 723.72 ± 34.28 807.93 ± 67.02 739.53 ± 29.64 1381.05 ± 66.70 796.69 ± 57.02 726.64 ± 24.38 2.1 1820
MIP-1α/CCL3 not detectable 1.4 836
MIP-1β/CCL4 not detectable 1.07 ± 0.07 1.45 ± 0.37 1.39 ± 0.22 1.22 ± 0.27 2.22 ± 0.24 1.55 ± 0.25 1.63 ± 0.49 2.0 1726
PDGF-BB 2.98 ± 0.80 381.57 ± 17.80 2.67 ± 0.45 1.54 ± 0.26 1.56 ± 0.29 538.39 ± 46.15 2.09 ± 0.39 1.67 ± 0.27 7.0 51933
RANTES/CCL5 not detectable 2.2 8617
TNF-α 6.54 ± 1.10 15.40 ± 0.64 6.38 ± 0.50 6.32 ± 0.38 5.05 ± 0.35 21.67 ± 0.66 7.08 ± 0.54 6.32 ± 0.57 5.8 95484
VEGF-A 1818.73 ± 244.50 5465.75 ± 179.62 1896.54 ± 116.96 2058.13 ± 195.85 1691.34 ± 179.39 6662.14 ± 513.77 2173.08 ± 306.62 1908.18 ± 202.61 5.5 56237
All cytokines/chemokines and growth factors detectable with the Bio-Plex Pro™ Human Cytokine, 
Chemokine and Growth Factor Assay are given in the first column. The detected concentration of these 
factors in culture supernatants from ARPE-19 cells in the absence/presence of vitreous, thrombin, hirudin 
and/or dabigatran is indicated in the second till ninth column. The two last columns indicate the lower limit 
of quantitation (LLOQ) and upper limit of quantitation (ULOQ). Cytokines/chemokines and growth factor 
concentrations are in (pg/ml). Values are the average of 4-6 samples ± SEM. Values in italic are outside 
limits of quantitation.
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Supplemental table 1. Bio-Plex Pro™ Human Cytokine, Chemokine, and Growth Factor Assay analysis
culture media culture media + 
thrombin
vitreous vitreous + 
dabigatran
vitreous + hirudin vitreous + 
thrombin
“vitreous + 
thrombin +
dabigatran”
“vitreous + 
thrombin +
hirudin”
LLOQ ULOQ
IL-1β 0.46 ± 0.8 0.84 ± 0.02 0.41 ± 0.02 0.41 ± 0.04 0.34 ± 0.02 1.44 ± 0.07 0.46 ± 0.05 0.40 ± 0.05 3.2 3261
IL-1rα not detectable 81.1 70487
IL-2 not detectable 2.1 17772
IL-4 0.39 ± 0.07 0.91 ± 0.04 0.34 ± 0.02 0.34 ± 0.02 0.27 ± 0.01 1.47 ± 0.07 0.38 ± 0.05 0.33 ± 0.04 2.2 3467
IL-5 not detectable 3.1 7380
IL-6 5.54 ± 1.48 430.39 ± 42.72 20.90 ± 5.39 20.87 ± 5.00 18.03 ± 5.60 1127.75 ± 132.20 23.55 ± 5.52 22.60 ± 8.44 2.3 18880
IL-7 3.98 ± 0.48 5.47 ± 0.16 3.54 ± 0.30 3.96 ± 0.30 3.59 ± 0.39 8.93 ± 0.44 3.97 ± 0.31 3.66 ± 0.44 3.1 6001
IL-8/CXCL8 46.45 ± 5.52 6634.67 ± 1445.81 247.85 ± 51.70 145.86 ± 48.29 103.71 ± 30.21 not detectable 159.14 ± 48.07 115.76 ± 32.89 1.9 26403
IL-9 10.71 ± 1.45 31.95 ± 1.12 9.05 ± 0.94 8.53 ± 0.98 6.70 ± 0.36 40.04 ± 1.29 9.96 ± 2.10 8.09 ± 0.99 2.1 7989
IL-10 13.95 ± 1.50 26.75 ± 0.97 14.64 ± 0.68 15.53 ± 0.95 13.82 ± 0.74 31.95 ± 1.19 16.65 ± 1.29 16.08 ± 1.83 2.2 8840
IL-12 (p70) 75.45 ±  6.18 143.39 ± 3.41 75.69 ± 3.64 79.81 ± 4.20 70.65 ± 3.68 165.47 ± 5.11 82.69 ± 5.93 78.67 ± 5.20 3.3 13099
IL-13 0.57 ± 0.10 0.74 ± 0.03 0.44 ± 0.03 0.46 ± 0.03 0.39 ± 0.03 1.11 ± 0.07 0.49 ± 0.07 0.42 ± 0.03 3.7 3137
IL-15 not detectable 2.1 2799
IL-17 not detectable 4.9 12235
FGFb 152.86 ± 45.33 212.11 ± 34.08 40.62 ± 9.65 49.23 ± 16.60 21.90 ± 1.96 159.56 ± 46.19 101.78 ± 67.76 31.23 ± 5.14 40.9 5824
Eotaxin not detectable 27.2 7581
G-CSF not detectable 2.4 11565
GM-CSF 42.16 ± 4.18 169.83 ± 6.79 24.61 ± 1.86 34.82 ± 4.50 30.05 ± 2.56 219.26 ± 20.68 34.93 ± 4.35 28.88 ± 2.74 63.3 6039
IFNγ not detectable 92.6 52719
IP-10/CXCL10 not detectable not detectable 16.86 ± 4.23 16.99 ± 4.14 15.53 ± 3.68 20.66 ± 5.27 6,03 18.83 ± 6.42 18.8 26867
MCP-1/CCL2 500.92 ± 46.28 1135.27 ± 142.22 723.72 ± 34.28 807.93 ± 67.02 739.53 ± 29.64 1381.05 ± 66.70 796.69 ± 57.02 726.64 ± 24.38 2.1 1820
MIP-1α/CCL3 not detectable 1.4 836
MIP-1β/CCL4 not detectable 1.07 ± 0.07 1.45 ± 0.37 1.39 ± 0.22 1.22 ± 0.27 2.22 ± 0.24 1.55 ± 0.25 1.63 ± 0.49 2.0 1726
PDGF-BB 2.98 ± 0.80 381.57 ± 17.80 2.67 ± 0.45 1.54 ± 0.26 1.56 ± 0.29 538.39 ± 46.15 2.09 ± 0.39 1.67 ± 0.27 7.0 51933
RANTES/CCL5 not detectable 2.2 8617
TNF-α 6.54 ± 1.10 15.40 ± 0.64 6.38 ± 0.50 6.32 ± 0.38 5.05 ± 0.35 21.67 ± 0.66 7.08 ± 0.54 6.32 ± 0.57 5.8 95484
VEGF-A 1818.73 ± 244.50 5465.75 ± 179.62 1896.54 ± 116.96 2058.13 ± 195.85 1691.34 ± 179.39 6662.14 ± 513.77 2173.08 ± 306.62 1908.18 ± 202.61 5.5 56237
All cytokines/chemokines and growth factors detectable with the Bio-Plex Pro™ Human Cytokine, 
Chemokine and Growth Factor Assay are given in the first column. The detected concentration of these 
factors in culture supernatants from ARPE-19 cells in the absence/presence of vitreous, thrombin, hirudin 
and/or dabigatran is indicated in the second till ninth column. The two last columns indicate the lower limit 
of quantitation (LLOQ) and upper limit of quantitation (ULOQ). Cytokines/chemokines and growth factor 
concentrations are in (pg/ml). Values are the average of 4-6 samples ± SEM. Values in italic are outside 
limits of quantitation.
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ABSTRACT
BACKGROUND/AIMS
Patients with rhegmatogenous retinal detachment (RRD) who develop postoperative 
proliferative vitreoretinopathy (PVR) have been found to have higher preoperative laser-flare 
values than RRD patients who do not develop this complication. Measurement of laser 
flare has therefore been proposed as an objective, rapid and non-invasive method for 
identifying high-risk patients. The purpose of our study was to validate the use of 
preoperative flare values as a predictor of PVR risk in two additional patient cohorts, and 
to confirm the sensitivity and specificity of this method for identifying high-risk patients.
METHODS
We combined data from two independent prospective studies: centre 1 (120 patients) and 
centre 2 (194 patients). Preoperative aqueous humour flare was measured with a Kowa 
FM-500 Laser Flare Meter. PVR was defined as redetachment due to the formation of 
traction membranes that required re-operation within six months of initial surgery. Logistic 
regression and ROC analysis determined whether higher preoperative flare values were 
associated with an increased risk of postoperative PVR.
RESULTS
PVR redetachment developed in 21/314 patients (6.7%). Median flare values differed 
significantly between centres, therefore analyses were done separately. Logistic regression 
showed a small but statistically significant increase in odds with increasing flare only for 
centre 2 (OR 1.014; p=.005). Areas under the ROC showed low sensitivity and specificity: 
centre 1 0.634(95% CI: 0.440 – 0.829) and centre 2 0.731(95% CI: 0.598 – 0.865). 
CONCLUSION
Preoperative laser flare measurements are inaccurate in discriminating between those 
patients with RRD at high and low risk of developing PVR.
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INTRODUCTION
Rhegmatogenous retinal detachment (RRD) is a common eye condition whose prevalence 
increases with age. While surgical repair is effective in most cases, in 5-10% of patients 
reattachment is complicated by the formation of epiretinal and/or subretinal contracting 
membranes.1 This complication is called proliferative vitreoretinopathy (PVR) and often 
leads to recurrent detachments and a poor prognosis in terms of regaining vision. 
While pharmaceutical drug therapies have been proposed for PVR – including anti-
inflammatory drugs, anti-proliferative drugs and heparin – all these drugs have potential 
side effects.2-7 Therefore, to optimise the benefit/risk ratio of drug therapies, it is crucial to 
select only those patients at high risk of developing PVR. 
Several risk prediction models have been proposed to help identify these high-risk patients. 
These models are based on clinical characteristics such as aphakia, vitreous haemorrhage, 
pre-operative PVR, extent and duration of detachment, and high vitreous levels of protein.8-10 
Also the presence of certain gene polymorphisms has been shown to be associated with 
a higher risk of PVR. 11 However, validation studies have shown the models to have a low 
sensitivity, specificity, and positive predictive value, making them unsuitable for supporting 
treatment decisions.12  
A different potential predictor for PVR development was found by Schröder et al.13 They 
found preoperative anterior chamber flare – caused by reflection of laser light by proteins 
in aqueous humour – to be a strong predictor for PVR development. Patients with a 
preoperative flare value higher than 15 photon count per millisecond (pc/ms), measured 
objectively with a laser flare meter, had a 16-fold higher risk of developing PVR.13
Based on these findings, measurement of laser flare would provide an objective, rapid and 
non-invasive method for identifying high-risk patients. The purpose of our study was 
therefore to validate the use of preoperative laser flare values as a predictor of PVR risk in 
two additional patient cohorts from Germany and the Netherlands, and to confirm the 
sensitivity and specificity of this method for identifying high-risk patients.
METHODS
The University of Kiel in Germany (Centre 1) and the Rotterdam Eye Hospital in The 
Netherlands (Centre 2) both conducted a prospective study on the predictive value of 
preoperative aqueous humour flare values on the development of PVR. As both studies 
were set up independent from each other, study protocols differed slightly.
In centre 1 one-hundred and thirty-eight patients with a primary RRD were included in the 
study between April 2012 and June 2015. From January 2014 until October 2014, two-
hundred and eight patients with a primary RRD were included in centre 2. Patients with 
additional ocular pathologies such as active uveitis, active vasculitis, retinal vein occlusion, 
diabetic macular oedema, proliferative diabetic retinopathy, exudative age-related macular 
degeneration, and primary PVR grade C or higher, were excluded. Approval was obtained 
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from the research ethics committee and institutional review board. All patients gave written 
informed consent.
We measured aqueous flare in the anterior chamber with a Kowa FM-500 Laser Flare Meter 
(Kowa Company Ltd. Japan) pre-operatively in both eyes. In centre 1, we made ten 
measurements per eye on the morning prior to surgery in an undilated eye and recorded 
the mean. In centre 2, we made seven measurements for each eye and discarded the 
highest and the lowest value, leaving the average and standard deviation of five 
measurements. The measurement of the study eye was made 15 minutes after instillation 
of a drop of 0.5% tropicamide, while the fellow eye remained undilated. 
We recorded the lens status, visual acuity, type of surgery, number of retinal tears, the 
extent of retinal detachment, the presence of rolled over edges, and medication history. 
Standard treatment after surgery in centre 1 consisted of the administration of 
dexamethasone and gentamicin eye drops (Dexamytrex®) five times daily, which was 
reduced during six weeks. In centre 2 therapy consisted of four times daily prednisolone 
acetate eye drops (Pred Forte®) which were reduced during four weeks. Deviations from 
this protocol were also recorded.
Clinically relevant PVR was defined as re-operation for redetachment due to PVR 
membranes, within six months of initial surgery. This information was extracted from the 
patient’s file or when not conclusive by contacting the patient or his/her referring 
ophthalmologist. 
ANALYSIS
We compared patient characteristics for the two centres using an independent samples 
t-test and Chi-square tests. To compare the flare values an independent-Samples Kruskal-
Wallis test and Mann-Whitney U-tests were used. We performed logistic regression to see 
to what extent a higher preoperative flare value increased the risk of postoperative PVR 
development. ROC analysis was used to test the sensitivity and specificity of preoperative 
flare values in discriminating between PVR and no PVR development. The Wilcoxon signed 
rank test for related samples was used to compare flare values in undilated versus dilated 
eyes and with versus without fluorescein administration. Statistical analyses were 
performed with IBM SPSS statistics version 21. 
RESULTS 
We recruited a total of 346 patients at the two centres, but we excluded 32 of them from 
the analysis for various reasons. For details see Figure 1. The characteristics of the 
remaining 314 patients are tabulated in Table 1. The two patient populations were 
comparable and differed only in the type of surgery patients received and in the number 
of patients who presented with their macula still attached. Out of 314 patients, 46 patients 
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needed additional surgery within six months. We diagnosed only 21 of these patients with 
a redetachment due to epiretinal membranes or subretinal strands associated with PVR. 
Six patients had a persistent detachment (resurgery within one week) due to a missed or 
insufficiently closed break and the remaining patients had redetachments caused by new 
breaks, not completely closed old breaks, a macular hole or giant tear, without any signs 
of traction due to epiretinal membranes or subretinal strands. 
PREOPERATIVE FLARE VALUES
The flare values measured in centre 1 were significantly and systematically higher than in 
centre 2. We therefore decided to perform logistic regression and ROC analysis for each 
centre separately. Table 2 shows these median preoperative flare values per centre and 
the results of the Mann-Whitney U test for the whole patient group and for the different 
subgroups. Flare values are expressed in pc/ms. Figure 2 shows the distribution of flare 
values and their median for the different centres and groups. 
For each centre, an independent-Samples Kruskal-Wallis test was performed to compare 
preoperative flare values of healthy fellow eyes, eyes with no PVR redetachment and eyes 
with PVR redetachment. For both centres significance was demonstrated (p < .001). Post 
hoc analysis per centre involved pairwise comparisons among the three groups. Statistically 
significant differences were demonstrated for all comparisons, except for the comparison 
between patients with and without a PVR redetachment in centre 1 (adjusted significance 
p = .843). 
Figure 1. Flowchart of patient selection
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Table 1. Patient characteristics of the two study populations
Centre 1
(n=120)
Centre 2
 (n=194)
Age (yr.)     
mean (SD*) 61 (11.9) 59 (11.0)
Gender, n (%)     
male 79 (66) 126 (65)
Lens status preoperatively
phakic 68 (57) 124 (64)
pseudophakic 52 (43) 68 (35)
aphakic - 2 (1)
Surgical procedure, n (%)     **
Scleral buckle (SB) 17 (14) 70 (36)
PPV + gas 31 (26) 104 (54)
PPV + oil - 15 (8)
SB + PPV + gas 52 (43) -
SB + PPV + oil 20 (17) -
PPV + air - 5 (3)
Extent of detachment, n (%)     
< 1 quadrant - 7 (3.6)
1 quadrant 23 (19.2) 45 (23.2)
2 quadrants 67 (55.8) 97 (50.0)
3 quadrants 22 (18.3) 30 (15.5)
4 quadrants 8 (6.7) 15 (7.7)
Macula attached, n (%) **
Yes 44 (36.7) 100 (51.5)
Primary success rate, n (%) 104 (87) 164 (85)
Persistent detachment, n (%) 2 (1.6) 4 (2.1)
PVR development, n (%)
Yes 9 (7.5) 12 (6.2)
*  SD = standard deviation. ** = Significant difference between centres p < 0.05, Chi-Square
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PREOPERATIVE FLARE VALUES AND PVR REDETACHMENT RISK
The individual logistic regression showed a significant result only for centre 2. An increase 
of 1 pc/ms of the preoperative flare value increased the odds of PVR redetachment by 
1.014 (see Table 3). An increase of 10 pc/ms increased the odds by 1.15. When we 
combined the data from the two centres and controlled for research centre, we found a 
smaller odds ratio of 1.008. The correct prediction of PVR cases or the correct classification 
of patients in general did not improve by including preoperative flare. In addition, we tested 
whether a higher preoperative flare value was a predictor for any redetachment (with or 
without signs of PVR), this analysis also showed a significant result only for centre 2 and 
the combined data (see Table 3).  
SENSITIVITY AND SPECIFICITY 
The area under the ROC curve for centre 1 was 0.634 (95% CI: 0.440 – 0.829). At a cut-off 
value of 10 pc/ms, the accompanying sensitivity and specificity were 89% and 22%. A 
higher cut-off value of 15 pc/ms, showed higher specificity (37%) and somewhat lower 
sensitivity (78%).  For centre 2 the area under the ROC curve was higher (0.731; 95% CI: 
0.598 – 0.865). The cut-off values of 10 and 15 pc/ms showed a sensitivity and specificity 
of 75% and 50%, and 50% and 76%.
The probability that a patient with a preoperative flare value above 15 pc/ms would develop 
a PVR redetachment (positive predictive value) was 9 and 12 percent for centre 1 and 2, 
based on the observed prevalence in these centres. 
Figure 2 Boxplot showing the distribution of flare values on a logarithmic scale for healthy fellow eyes, 
patients with no PVR (including patients with redetachments due to other reasons) and patients with PVR.
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Table 2. Median flare values (pc/ms) in subgroups and healthy fellow eyes
Centre 1
(n=120)
Centre 2
(n=194)
P*
median (range) median (range)
RD 17.7 (5.0-312.0)  10.2 (3.2-263.8) < 0.001
phakic 16.0 (5.0-312.0) 9.1 (3.2-263.8)
pseudophakic 23.1 (5.4-76.1) 12.4 (4.4-196.4)
aphakic - 17.4 (5.9-28.8)
No PVR redetachment 17.1 (5.0-312.0) 10.0 (3.2-263.8) < 0.001
phakic 16.0 (5.0-312.0) 8.5 (3.2-263.8)
pseudophakic 22.3 (5.4-76.1) 12.3 (4.4-126.0)
aphakic - 17.4 (5.9-28.8)
PVR redetachment  32.2 (6.9-183.9) 15.8 (8.3-196.4) 0.808 
phakic 29.6 (6.9-183.9) 16.7 (9.8-187.8)
pseudophakic 32.2 (10.6-57.6) 14.8 (8.3-196.4)
Extent of detachment     
< 1 quadrant - 7.3 (3.2-9.9)
1 quadrant 10.0 (5.4-33.0) 7.6 (3.2-37.9)
2 quadrants 17.8 (5.0-107.0) 10.1 (3.3-67.4)
3 quadrants 27.0 (7.2-312.0) 11.9 (5.7-196.5)
4 quadrants 131.9 (17.0-292.1) 62.3 (10.4-263.8)
Macula On 11.4 (5.0-86.0) 8.5 (3.2-49.4) 0.001
Macula Off 23.2 (6.9-312.0) 12.0 (4.0-263.8) < 0.001
Healthy fellow eyes 9.7 (3.1-29.7) 6.6 (2.4-16.2) < 0.001
* independent Samples Mann-Whitney U test between centres. Significance level after
Bonferroni correction p  = 0.008   Analysis was not performed for extent of detachment 
Table 3. Results from logistic regression analyses for redetachment risk.
Covariate(s) P Odds Ratio 95% confidence 
interval
PVR redetachment 
Centre 1 Preoperative flare .495 1.004 0.993 – 1.014
Centre 2 Preoperative flare .005 1.014 1.004 – 1.024
Combined Preoperative flare .015 1.008 1.002 – 1.015
Research centre .948 1.031 0.408 – 2.607
Any redetachment 
Centre 1 Preoperative flare .233 1.005 0.997 – 1.013
Centre 2 Preoperative flare .012 1.012 1.003 – 1.021
Combined Preoperative flare .008 1.008 1.002 – 1.014
Research centre .342 0.719 0.364 – 1.419
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INFLUENCE OF DILATING EYE DROPS ON THE FLARE VALUE
As flare values were systematically higher in centre 1 compared with centre 2, we 
performed additional analyses in an attempt to explain these differences. 
First, we compared 27 study patients from centre 1 in whom measurements were 
performed in both eyes during the study in undilated and dilated state 30 minutes apart. 
The Wilcoxon signed rank test for related samples revealed a significantly lower flare value 
in the dilated state (OD p=.002; OS p < .0001). The median differences were -2.3 pc/ms 
(Interquartile range(IQR): -4.3 – -0.3) and -2.7 pc/ms (-4.1 – -0.6). 
Second, we compared 147 healthy fellow eyes from study patients in centre 2. Fellow eyes 
were measured in undilated and dilated state at two different standard visits, six weeks 
apart. Also here we found a significantly lower value in the dilated state (p <.001). The 
median difference was -0.6 pc/ms (IQR -2.4 – 0.4), less than the values found in centre 1.
 
INFLUENCE OF FLUORESCEIN 
To test the possible influence of fluorescein on the height of the flare value we measured 
10 healthy volunteers with undilated pupils. Next, we used a fluorescein strip and 
oxybuprocaine 0.4% to instil fluorescein in the eye. After an hour we measured flare again. 
The related samples Wilcoxon signed rank test showed no significant difference (p = .359). 
DISCUSSION
The results of our study suggest that preoperative flare values are a poor predictor of 
postoperative PVR development. Although the logistic regression analysis showed a 
significant result for one of the two centres (OR 1.014), this did not improve classification 
of patients into their respective groups (PVR vs. no PVR development). In addition, the 
sensitivity and specificity of preoperative flare at different cut-off values were too low to 
adequately filter out the high-risk patients. As a consequence, we were unable to validate 
the findings of Schröder et al, although they used the same flare meter type and calibration 
protocol.13
During the analysis of the data, we discovered discrepancies between the two centres. 
One such discrepancy was a statistically significant difference in median flare values; the 
median value in patients with no PVR was higher for centre 1 (17.7 pc/ms) than for centre 
2 (10.2 pc/ms). Also, median flare values of healthy fellow eyes were significantly higher. 
A comparison of the values with those of previous studies using flare measurement 
suggests that centre 1 is the one whose values are higher.13-16 Previously reported mean 
values range from 3.7 to 6.5 pc/ms in healthy individuals and a median of 10 pc/ms in 
patients with a rhegmatogenous retinal detachment. We, therefore, decided to analyse 
the results separately for each centre. 
Although the two centres conducted their study independently from each other, the study 
protocols differed only slightly. When we compared inclusion and exclusion criteria, 
measurement method and conditions, and primary outcome, we found that the centres 
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had similar levels of background lighting, both used the same Kowa Laser Flare Meter type 
and calibrated it monthly. There were however two apparent differences. 
The first difference was the number of measurements made per eye. Centre 1 used the 
mean of ten measurements per eye, excluding any measurements deviating more than two 
standard deviations from this mean. Centre 2 made seven measurements and excluded the 
highest and the lowest value, leaving a mean of five measurements. However, we do not 
expect this difference to add to the large difference in median flare values that we observed. 
The second difference was that while centre 2 used dilating eye drops, centre 1 did not. 
From the literature, it is known that dilating eye drops reduce flare during the first one to 
two hours after instillation.17-19 The mechanism is not completely understood, but it seems 
to be a pharmacological effect rather than a reduction of background noise by a larger pupil 
size.20 Tropicamide was reported to decrease the flare value by approximately 10-30% in 
healthy eyes.19, 20 To determine whether this was likely to have had a major influence on 
our flare results, we did two additional analyses. Both analyses showed a significant lower 
flare value in dilated state, but the absolute median difference was less than 3 pc/ms in 
centre 1 and 0.6 pc/ms in centre 2. Although the use of dilating eye drops does not explain 
the entire difference found between the two centres, it might have contributed significantly. 
What stood out in both centres was the large range of values and a large number of outliers 
(3.2 – 312 pc/ms). This large number of outliers in the no PVR group versus the low number 
of PVR cases makes a distinction between these groups difficult. Possibly the variation in 
values is more dependent on the timepoint at which flare is measured, rather than on a 
difference in PVR status.  When patients present at the emergency department, they are 
subjected to various examinations that require the use of multiple eye drops and undergo 
various manipulations of the eye. Manipulations such as gonioscopy and scleral indentation 
might cause an inflammatory reaction leading to a rise in flare. In centre 1 examination 
with scleral indentation was often performed one day before the flare measurements. In 
contrast, centre 2 did not routinely perform scleral indentation at admission. This might be 
another reason explaining the higher flare values in centre 1. However, we did not find any 
literature on this topic and this explanation remains speculative. 
Another possibility might be that the presence of fluorescein in the anterior chamber might 
increase flare. We therefore tested this by measuring flare before and after the 
administration of fluorescein in ten volunteers, but we could not detect a significant 
difference (p=.359). As the intensity of scattered light is proportional to particle diameter 
and fluorescein is approximately 200 times smaller in weight than albumin, the influence 
of the small concentration fluorescein on the flare value is likely to be negligible compared 
to the influence of proteins.
In conclusion, the wide variation and overlap in flare values between patients with and 
without PVR implicate that the measurement of aqueous humour flare with a Kowa Laser 
Flare Meter is inaccurate in discriminating between those patients with RRD at high and 
low risk of developing PVR. It should be further explored whether the addition of aqueous 
flare as a parameter to existing risk formulae would increase their predictive value.  
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ABSTRACT
BACKGROUND/AIMS
As some surgical procedures have been shown to increase postoperative flare values and 
thus contribute to blood-ocular barrier breakdown, retinal reattachment surgery might 
influence the risk of developing proliferative vitreoretinopathy (PVR). Therefore, we 
investigated whether postoperative aqueous flare values are a surrogate marker for the 
development of postoperative PVR. 
METHODS
We prospectively included 195 patients with primary rhegmatogenous retinal detachment 
(RRD) and measured aqueous laser flare preoperatively, and at two and six weeks 
postoperatively (Kowa FM-500 Laser Flare Meter). Postoperative PVR was defined as 
reoperation for redetachment due to PVR membranes, within six months of initial surgery. 
Logistic regression and ROC analysis determined whether higher postoperative flare values 
were associated with an increased risk of developing PVR later on. 
RESULTS
Reoperation for postoperative PVR was needed in 12 (6.2%) patients;  in 18(9.2%) 
reoperation was not related to PVR. The median flare value for patients who would develop 
PVR was significantly higher than that of patients who would not develop PVR, both at two 
weeks (p=0.001) and six weeks (p<0.001) postoperatively. Logistic regression analyses 
showed that a higher flare value significantly increased the odds of developing PVR, either 
at two weeks (odds ratio (OR) 1.027; 95%CI: 1.010-1.044) or six weeks (OR 1.076; 95%CI: 
1.038-1.115).
CONCLUSION
Flare values both at two and six weeks postoperatively seem a good surrogate marker in 
terms of sensitivity and specificity for the development of postoperative PVR but have only 
a modest PPV. The two-week value would be more useful in terms of early recognition of 
high-risk patients and hence give the possibility to better study effects of treatment 
methods.
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INTRODUCTION
Anterior chamber aqueous flare – a surrogate marker for inflammation – has been proposed 
as a predictor for proliferative vitreoretinopathy (PVR) in patients with a rhegmatogenous 
retinal detachment (RRD).1-3 In contrast to previous reports, we recently reported that the 
preoperative aqueous flare value is not a strong predictor for the development of PVR 
postoperatively.4 
Although a minority of patients without a history of ocular disease presents with PVR prior 
to retinal reattachment surgery, in industrialised countries 5-10% of patients typically 
develop PVR in two weeks to six months after surgery. Some of these surgical procedures 
have been shown to increase postoperative flare values and thus contribute to blood-ocular 
barrier breakdown.5-8 Therefore, retinal reattachment surgery is thought to possibly influence 
the risk of developing postoperative PVR.9
The flare value after surgery might therefore be a better indication of the development of 
postoperative PVR than the preoperative flare value. We investigated whether postoperative 
aqueous flare values or a change in aqueous flare values from preoperative to postoperative 
are a surrogate marker for the development of postoperative PVR. 
METHODS
PATIENTS 
From January 2014 until October 2014 we included 208 patients with RRD admitted to 
the Rotterdam Eye Hospital, the Netherlands. Patients with additional ocular pathologies 
such as active uveitis, active vasculitis, retinal vein occlusion, diabetic macular oedema, 
proliferative diabetic retinopathy, exudative age-related macular degeneration, and primary 
PVR grade C or higher, were excluded. Postoperative PVR was defined as reoperation for 
redetachment due to PVR membranes, within six months of initial surgery. This information 
was extracted from the patient’s file or, when not conclusive, by contacting either the 
patient or his/her current physician. The standardised surgical reports of the reoperations 
and the patient’s file were evaluated by one vitreoretinal surgeon (masked to flare values) 
who scored each reoperation as either not PVR related or PVR related. 
The study followed the tenets of the Declaration of Helsinki and was approved by the 
institutional review board. All patients gave written informed consent. This patient cohort 
has been part of a previously published report with a different research question exclusively 
on preoperative measurements.4
FLARE MEASUREMENTS
Aqueous laser flare of the anterior chamber was measured preoperatively and during regular 
postoperative visits at two and six weeks with a Kowa FM-500 Laser Flare Meter (Kowa 
Company Ltd. Tokyo, Japan). We performed seven measurements 15 minutes after 
instillation of 0.5% tropicamide eye drops. The highest and the lowest value were discarded, 
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leaving an average of five measurements. In addition, we recorded the preoperative and 
postoperative lens status, the extent of retinal detachment, number of horseshoe tears, 
presence of curled edges during surgery, type of surgery, and medication history. In all 
patients undergoing a vitrectomy procedure triamcinolone (Kenacort®) was used to 
visualize the vitreous during vitreous removal. Standard treatment after surgery consisted 
of a subconjunctival injection of betamethasone (Celestone® 4mg) and of four times daily 
prednisolone acetate eye drops (Pred Forte®) which were tapered over four weeks. 
Deviations from this protocol were also recorded.
SAMPLE SIZE
From previous measurements and other studies, it was known that flare values do not 
follow a normal distribution and that non-inflamed healthy eyes have (10log-transformed) 
flare values of 0.7 ± 0.3.6, 7, 10 For the purpose of the sample size calculation of the original 
study it was assumed that the standard deviation (SD) would be slightly higher (SD=0.4).4 
The incidence of PVR was estimated at 10%, the two-sided significance level was set at 
⁰=0.05, power at P=0.80, and a factor two increase in flare value was thought to be clinically 
relevant. This led to a sample size of 176 eyes of which at least 16 eyes were expected 
to develop postoperative PVR. 
STATISTICAL ANALYSIS
Since aqueous flare values are not normally distributed we looked at median flare values 
and used non-parametric tests. Patients who required reoperation for another indication 
than PVR were displayed as a separate group but for the logistic regression and ROC 
analysis they were included in the uncomplicated RRD group. Median flare values of the 
three groups were compared using a Kruskal-Wallis test with pairwise comparisons for 
both time points (two and six weeks).
We performed logistic regression to assess to what extent a higher postoperative flare value 
at either two or six weeks increased the risk of postoperative PVR development. ROC analysis 
was used to test the sensitivity and specificity of postoperative flare values in discriminating 
between PVR and no PVR development, and to define the optimal cut-off point. A Mann-
Whitney U-test was used to compare the individual changes in flare values from preoperative 
to two weeks postoperatively between the two groups. Statistical analyses were performed 
with IBM SPSS statistics version 21 (IBM Corp., Armonk, NY, USA).
RESULTS
We included 208 patients of which five patients were excluded due to other ocular 
pathology than RRD, three had preoperative PVR, two patients were lost to follow-up, two 
had multiple failed flare measurements and one received only laser treatment. The 
characteristics of the remaining 195 patients are shown in Table 1. Thirty patients (15%) 
underwent reoperation, out of whom four patients had a persistent detachment (reoperation 
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within one week) and 12 patients (6.2%) developed postoperative PVR for which surgery 
was performed. The remaining 14 patients had redetachments caused by new breaks (n= 
8), not completely closed old breaks (n= 4), a macular hole (n= 1) or giant tear (n= 1), 
without any signs of traction due to epiretinal membranes or subretinal strands. The median 
time until reoperation was 49 days (range 12-183 days) for patients who had developed 
PVR and 20 days (range 2-139 days) for reoperation due to other reasons.
Table 1. Patient characteristics of 195 patients with a rhegmatogenous retinal detachment
Characteristic Uncomplicated 
RRD (n=165)
Reoperation, 
no PVR (n=18)
Postoperative 
PVR (n=12)
Age (year)   
mean (SD) 59 ± 11 55 ± 9 69 ± 9
Gender, n (%)   
male 106 (64) 14 (78) 7 (58)
Lens status before surgery, n (%)
phakic 102 (61.8) 16 (88.9) 7 (58.3)
pseudophakic 62 (37.6) 1 (5.6) 5 (41.7)
aphakic 1 (0.6) 1 (5.6) -
Surgical procedure, n (%)   
Scleral buckling 56 (33.9) 13 (72.2) 1 (8.3)
PPV + gas 85 (51.5) 3 (16.7) 5 (41.7)
PPV + gas + CE 12 (7.3) 2 (11.1) 3 (25.0)
PPV + oil 10 (6.1) - 3 (25.0)
PPV + oil + CE 2 (1.2) - -
Extent of detachment, n (%)   
< 1 quadrant 6 (3.6) 1 (5.6) 1 (8.3)
1 quadrant 40 (24.2) 4 (22.2) 1 (8.3)
2 quadrants 84 (50.9) 10 (55.6) 2 (16.7)
3 quadrants 25 (15.2) 3 (16.7) 3 (25.0)
4 quadrants 10 (6.1) - 5 (41.7)
Macula attached, n (%) 86 (52.1) 10 (55.6) 4 (33.3)
Preoperative hypotony, n (%)  (IOP ≤ 4 mmHg) 2 (1.2) - 1 (8.3)
Primary success, n (%) 165 (85)
Persistent detachment, n (%) 4 (2.1)
CE = cataract extraction, IOP = intraocular pressure, PPV = pars plana vitrectomy, RRD = Rhegmatogenous 
retinal detachment, SD = standard deviation
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POSTOPERATIVE FLARE VALUES
At two weeks postoperatively, the pairwise comparisons showed a significant difference 
between patients who would develop PVR postoperatively and patients with uncomplicated 
RRD (adjusted p=0.001; n=10 vs. n=162). The median flare value of patients with a 
reoperation due to other reasons (n=12) did not differ significantly from the two other 
groups (adjusted p= 0.526 and p= 0.176), at two weeks postoperatively. At six weeks, the 
flare values of patients who would develop PVR (n= 8) remained higher than those of 
patients who received a reoperation for another reason (adjusted p = 0.002; n= 5) and of 
patients with uncomplicated RRD (adjusted p < 0.001; n= 164). 
Since eight patients required reoperation before their evaluation visit at two weeks and 
nine patients required reoperation before their evaluation visit at six weeks, the flare values 
of those visits are missing. Figure 1 shows the median flare values over time for the three 
mentioned groups. The whiskers represent the interquartile ranges. 
POSTOPERATIVE FLARE VALUE AND RISK OF PVR DEVELOPMENT
We tested whether a higher flare value at either two or six weeks after surgery was a 
surrogate marker for a future PVR redetachment. Patients requiring reoperation due to 
other reasons than PVR were included in the uncomplicated group.  The logistic regression 
analysis showed a significant result for both time points (see Table 2).  
Figure 1 Median flare values over time for the three different groups of patients with a 
rhegmatogenous retinal detachment. The whiskers represent the interquartile ranges (25-
75%)
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SENSITIVITY, SPECIFICITY, AND POSITIVE PREDICTIVE VALUE
The ROC analysis showed high area under the ROC curves for both the two-week 
postoperative values (0.84; 95% CI: 0.76 – 0.93) and the six-week postoperative values 
(0.92; 95% CI: 0.86 – 0.97). A cut-off value of 34 pc/ms two weeks postoperatively led to 
both a sensitivity and specificity of 80% (see Figure 2). For the values obtained at six 
weeks, the optimal cut-off value was 27 pc/ms, with an accompanying sensitivity and 
specificity of 100% and 83%. A cut-off of 27 pc/ms for the two-week postoperative values, 
showed 85% sensitivity and 69% specificity. The probability that a patient with a flare value 
above 27 pc/ms at two or six weeks postoperatively developed a PVR redetachment – the 
positive predictive value – was 14.5 and 22 percent. The positive predictive value with a 
cut-off of 34 pc/ms two weeks postoperatively was 18%. 
Table 2. Results from logistic regression comparing uncomplicated rhegmatogenous retinal detachment 
patients with patients who developed proliferative vitreoretinopathy.
P Odds Ratio 95% confidence 
interval
N
Flare value 2 weeks postoperatively 0.002 1.027 1.010-1.044 10/174
Flare value 6 weeks postoperatively <0.001 1.076 1.038-1.115 8/169
Figure 2. ROC analyses of flare values at two and six weeks postoperatively and postoperative proliferative 
vitreoretinopathy (PVR) development. Patients requiring reoperation due to other reasons than PVR are 
included in the uncomplicated group
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ABSOLUTE CHANGE IN FLARE VALUES FROM PREOPERATIVELY TO TWO 
WEEKS POSTOPERATIVELY
We calculated the individual absolute change in pc/ms from the preoperative value to the 
two-week flare value for patients who would not develop PVR (uncomplicated RRD) - 
including patients with reoperations due to other reasons - and for patients who would 
later develop postoperative PVR. A positive value in Figure 3 means that the flare value 
increased after surgery and a negative value means a decrease in flare value. Figure 3 
shows that the flare value in patients who would later develop postoperative PVR increased 
in half of the patients and decreased in the other half. In patients who would not develop 
PVR, the flare value increased slightly in most cases. The distribution of differences was 
not significantly different between the two groups (Mann-Whitney U p= 0.672).
Figure 3. Histogram of absolute differences between the preoperative value and postoperative value at 2 
weeks. A positive value means an increase after surgery; a negative value a decrease after surgery.
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DISCUSSION
The logistic regression analysis showed that a higher postoperative flare value at either 
two or six weeks increased the chance of developing postoperative PVR (Table 2). The 
ROC analysis provided insight into the optimal cut-off values, which is a balance between 
not missing any patients who will develop postoperative PVR (sensitivity) and not labelling 
too many patients incorrectly as high-risk patients (specificity). The area under the ROC 
curve showed a better result for the six-week values, due to reaching 100% sensitivity 
and a good specificity. The accompanying cut-off value was 27 pc/ms. None of the eight 
patients who had not yet developed postoperative PVR at that point had a flare value below 
this value and 28 out of 183 patients who would not develop PVR had a flare value above 
27 pc/ms (specificity 83%). For the two-week values, the optimum was 80% sensitivity 
with 80% specificity and an accompanying cut-off value of 34 pc/ms. 
Although the ROC analyses showed high sensitivity and specificity at a cut-off value of 34 
pc/ms and 27 pc/ms at two and six weeks postoperatively, this led to positive predictive 
values of only 18% and 22%. The main reason for this was the low prevalence of 
postoperative PVR in our study (6.2%). Previously, we concluded that preoperative flare 
values are inaccurate in discriminating between high and low risk of developing PVR. While 
the logistic regression analysis showed a statistically significant value (p = 0.005), the 
accompanying odds ratio was low (1.014) and at a cut-off value of 15 pc/ms the low 
sensitivity (50%), specificity (76%) led to a positive predictive value of only 12%.4 The 
choice of using a test with a relatively low positive predictive value and thus a high false 
discovery rate depends on the consequences and risks for the patient associated with a 
positive test, such as possible side-effects of the treatment initiated. However, the use of 
postoperative flare would improve the selection of patients by three times relative to the 
prevalence in our unselected cohort, and would miss fewer patients that would later 
develop PVR than when using the preoperative value. In a new study design, this could 
be of value to improve the ratio between cases and controls. 
Although the six-week measurements proved to be a better marker for later PVR than the 
two-week measurements, the two-week measurements would be more useful in terms 
of earlier recognition of high risk for PVR and subsequently the possibility to start a 
treatment. Moreover, at two weeks fewer patients will have already experienced a PVR 
redetachment. Postoperative therapeutic options would be the administration of oral drugs 
or injections when such a treatment would be available and effective.11-17 Both postoperative 
measurements could be used by ophthalmologists to monitor inflammation and study 
treatment methods. 
The absolute flare value was a better surrogate marker for postoperative PVR development 
than the change in flare value. While the overall trend in flare values was an increase after 
surgery followed by a decrease towards six weeks, the individual changes from the 
preoperative flare value to the postoperative flare value at two weeks did not show a clear 
trend. This was highlighted in the ten patients who would later develop PVR: flare values 
increased in five cases but decreased in the five other cases. 
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The absence of a clear trend might be the result of specific proceedings and choices by 
the surgeon and/or patient during surgery and the early postoperative phase. Patients who 
underwent a vitrectomy procedure seemed to have higher postoperative flare values than 
patients who underwent scleral buckling, independent of the number of quadrants 
detachment (data not shown). In addition, factors such as the occurrence of complications, 
duration of surgery, choice of vital dyes, manipulation due to indentation and the use of 
antibiotics and/or steroids, may influence the inflammatory response. Figuring out the 
individual importance of these factors would require an extremely large sample size, 
whereas the postoperative flare value represents the sum of these factors. 
Adding the outcome of postoperative aqueous flare measurements to existing risk 
prediction models could possibly increase its value. The size of a detachment is a well-
known risk factor for the development of PVR, but the size of the detachment is also 
correlated to flare. 1, 2 In our study, this association was the strongest for preoperative flare 
and higher number of quadrants detachment (rs = 0.42, p < 0.001), for postoperative flare 
this association was weak (rs = 0.20, p = 0.005). In addition, correcting for the number of 
quadrants detachment in the logistic regression analysis did not change the odds ratio for 
the postoperative flare value (data not shown). 
These results should, however, be interpreted with caution due to a lower prevalence of 
postoperative PVR in our sample than anticipated. In conclusion, postoperative flare values 
two weeks after RRD surgery are a reasonable surrogate marker for the development of 
postoperative PVR. These results should be validated in other cohorts including more 
patients with postoperative PVR. 
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INTRODUCTION
In recent years there has been a general tendency towards using pars plana vitrectomy 
(PPV) for uncomplicated rhegmatogenous retinal detachment (RRD) instead of scleral 
buckling (SB).
In pseudophakic patients, PPV has become the standard surgical approach but also in 
phakic patients this trend is observable. With the advances of smaller-gauge PPV 
techniques, surgical trauma appears to be less, which is thought to result in lower 
postoperative inflammation and better results.1 Several studies, however, showed better 
functional results after SB.2,3 In addition, a systematic review described a higher risk of 
proliferative vitreoretinopathy (PVR) after PPV.4 
METHODS AND RESULTS
In a prospective study in patients with primary RRD to find predictors for the development 
of PVR, we measured preoperative and postoperative inflammation after SB and PPV by 
means of laser flare photometry.5 Mean postoperative flare values at different time-points 
after SB and PPV have been previously reported by others but have not been directly 
compared.6, 7 As the extent of the detachment might influence both the surgical approach 
as well as postoperative flare, we performed a subanalysis of our phakic patients in our 
previously published cohort to study whether SB and PPV produce comparable postoperative 
inflammation. Aqueous laser flare was measured during regular postoperative visits at two 
and six weeks with a Kowa FM-500 Laser Flare Meter (Kowa Company; Tokyo, Japan). We 
performed seven measurements 15 minutes after instillation of 0.5% tropicamide eye 
drops. The highest and the lowest value were discarded, leaving an average of five 
measurements. Postoperatively, patients received four times daily prednisolone acetate 
eye drops which were tapered over four weeks.5 
From the original study population, 115 patients were phakic preoperatively. In this group, 
62 patients underwent SB, 29 patients underwent PPV with gas, 6 patients underwent 
PPV with oil, and 18 patients a combination of PPV, cataract extraction (CE) and IOL 
implantation. Postoperative flare values after SB and PPV were compared using the 
independent samples Mann-Whitney U test for each quadrant separately. For sample size 
purposes, all patients that underwent PPV were combined. The results in Figure 1 show 
that postoperative flare is significantly higher after PPV than SB, independent of the size 
of the detachment. Both at two weeks and six weeks postoperatively. 
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Figure 6.
Boxplot showing postoperative flare values at two (A) and six (B) weeks, split up by size of detachment. 
Values are shown as photoncount per millisecond (pc/ms) on a logarithmic scale.  P-values refer to the 
independent samples Mann-Whitney U test.
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DISCUSSION
Due to the small sample size, we chose to cluster all patients treated with PPV. 
Pseudophakic patients, however, often have higher flare values.4 Therefore, the inclusion 
of patients with a combined CE surgery might have led to higher postoperative flare values 
in the PPV group. Table 1 indeed shows that the median flare value after PPV for two-
quadrants detachment might have been higher due to the inclusion of PPV with CE (no 
statistics performed). Overall, however, the median flare value after PPV is at least two 
times higher than after SB. 
A second factor that might have contributed to higher flare values in the PPV group is age. 
SB is usually preferred in the younger population and flare is described to increase with 
age.8 Although the SB group was somewhat younger than the PPV group (mean 54±12 vs 
59±9 years; P = 0.01), this small effect cannot explain the large difference found between 
SB and PPV. Moreover, 82% of patients in the SB group received cryotherapy, which is 
known to increase flare.7
In conclusion, these results imply a more serious inflammatory reaction and a larger 
breakdown of the ocular barriers after PPV, which might contribute to better functional 
results after SB and a higher risk of PVR after PPV. 
Table 1. Median postoperative flare values for different surgical procedures split up by 
preoperative quadrants detachment. 
Number of quadrants Surgical procedure 2 weeks 6 weeks
N Median N Median
1 Scleral Buckling 17 9.2 16 6.9
Vitrectomy 13 27.8 11 14.8
Vitrectomy + CE 5 29.4 5 21.2
2 Scleral Buckling 35 9.5 34 7.7
Vitrectomy 12 20.0 12 14.6
Vitrectomy + CE 5 41.7 3 37.0
3 Scleral Buckling 9 9.2 8 10.0
Vitrectomy 8 34.8 8 23.6
Vitrectomy + CE 3 26.9 3 24.2
4 Scleral Buckling 1 4.5 1 5.7
Vitrectomy 2 47.6 2 58.0
Vitrectomy + CE 5 35.3 5 35.2
CE = cataract extraction
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Because of the potential role of thrombin in the development of PVR we looked into drugs 
that would be able to inhibit thrombin. One such drug is the direct and reversible thrombin 
inhibitor dabigatran (Pradaxa®) which has been on the Dutch market since 2010. One of 
its uses is the prevention of thromboembolic events after knee or hip replacement surgery. 
It is an oral alternative to the subcutaneous injections with for example dalteparin 
(Fragmin®). An oral drug has the advantage of being more patient friendly with repeated 
administration. Disadvantages are the possibility of systemic side effects and the uncertainty 
whether it reaches its target side in the eye. The latter we investigated in chapter 2.1. 
Twenty-eight patients with RRD who needed surgery received a single administration of 
220mg dabigatran two to eight hours prior to their surgery. During surgery, we collected 
vitreous or subretinal fluid and some blood. The concentrations of dabigatran were analysed 
using LC-MS/MS. The results showed that dabigatran does reach the eye but in much 
lower concentrations than in plasma. An unexpected finding was the concentration we 
measured in vitreous of a patient who was on daily dabigatran therapy. This concentration 
was approximately 10x higher than after a single administration. This finding piqued our 
interest on the question whether repeated administration would lead to higher intraocular 
levels. In chapter 2.2 we describe three additional patients who used dabigatran on a daily 
basis but underwent vitreous surgery for different reasons than RRD. Also in these patients 
the concentration of dabigatran was significantly higher than we measured after a single 
administration. 
However, is dabigatran able to inhibit the effects of thrombin and are these concentrations 
high enough? In chapter 2.3 we exposed cultured retinal pigment epithelial cells (ARPE19) 
to thrombin in combination with dabigatran or without. We found that thrombin and vitreous 
fluids containing thrombin activity induced CCL2, CXCL8, GM-CSF, IL-6 and PDGF-BB 
expression by ARPE-19 cells, which was inhibited by dabigatran. In addition, we tested 
whether the vitreous fluids containing dabigatran from the previous studies were able to 
inhibit thrombin activity. This appeared to only be the case for the higher dabigatran 
concentration after repeated oral intake (12.9 ng/ml).
In chapter 2.4 we tested the formation of thrombin in the form of F1+2 and elimination in 
the form of thrombin-antithrombin (TAT) complex in vitreous and subretinal fluid. We found 
that both F1+2 and TAT were significantly higher in patients with a retinal detachment 
compared to patients with a macular hole or macular pucker. However, between patients 
with and without PVR we could not detect a difference due to the large variation. Possibly, 
the balance between the different thrombin regulation mechanisms (TAT and α2M) and 
the overall health of the patient contribute to differences between patients and the risk of 
developing PVR. An additional aim of dabigatran treatment in the prevention of PVR could 
therefore be reducing α2M-thrombin formation by shifting the balance towards inactive 
TAT.
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Taken together the results of chapter 2, dabigatran seems to be able to inhibit intraocular 
thrombin, reaches the eye in high enough concentrations and is an interesting potential 
new drug for the prevention of PVR that deserves more research. 
However, considering the potential serious side effects that could occur with drugs such 
as dabigatran one would like to select patients with the highest risk of developing PVR and 
would thus benefit most from a drug therapy.  
Chapter 3 describes the use of aqueous flare measurements as a predictor for the 
development of postoperative PVR. Flare is the phenomenon that results from the reflection 
of light on particles such as inflammatory proteins. It can be compared to the effect seen 
when a light beam shines across a dark smokey room. Laser flare is an objective 
measurement of inflammation. Previous research found that a high preoperative flare value 
– measured with a Kowa laser flare meter – was a strong predictor for the development 
of postoperative PVR. However, we could not confirm these results in a cohort from 
Rotterdam and Kiel (Germany), as is described in chapter 3.1. We combined data from 
two independent prospective studies: Kiel (120 patients) and Rotterdam (194 patients). 
PVR was defined as redetachment due to the formation of traction membranes that 
required re-operation within six months of initial surgery. Logistic regression and ROC 
analysis determined whether higher preoperative flare values were associated with an 
increased risk of postoperative PVR.
PVR redetachment developed in 21/314 patients (6.7%). Median flare values differed 
significantly between centres, therefore analyses were done separately. Logistic regression 
showed a small but statistically significant increase in odds with increasing flare only for 
Rotterdam (OR 1.014; p=0.005). Areas under the ROC showed low sensitivity and 
specificity: Kiel 0.634(95% CI: 0.440 – 0.829) and Rotterdam 0.731(95% CI: 0.598 – 0.865). 
In addition, using the previous reported cut-off point of 15 pc/ms and our current prevalence 
led to a positive predictive value of only 12%. 
We concluded that preoperative laser flare measurements are inaccurate in discriminating 
between those patients with RRD at high and low risk of developing PVR.
Because also the surgery itself possibly contributes to inflammation and thus the flare 
value, we looked at the predictive value of postoperative flare values in chapter 3.2. In 
195 patients with a primary RRD, flare was measured two and six weeks after surgery. 
The endpoint was reoperation for PVR within six months of initial surgery. The median flare 
values of patients who would later develop PVR were significantly higher than those of 
patients with an uncomplicated course both at two and six weeks after surgery (median 
2wks: 43 vs. 15 pc/ms; p =0.001, median 6wks: 38 vs. 13 pc/ms; p < 0.001). In addition, 
both the logistic regression analysis and the ROC analysis showed a significant increased 
risk with a higher postoperative flare value. 
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The individual change of the flare value from preoperative to postoperative did not reveal 
a clear trend. For most patients with an uncomplicated course the flare value rose less 
than 10 pc/ms after surgery. In patients who would develop PVR the flare value rose in 
50% of patients and declined in the other 50%. The direction of the change seems 
therefore less important than the actual flare value that remains after surgery. This was 
further substantiated in chapter 3.3 as it becomes clear that a vitrectomy procedure 
induces a stronger inflammatory reaction than a scleral buckling procedure. This was 
independent of the size of the detachment. 
In conclusion, postoperative flare values two weeks after RRD surgery are a reasonable 
surrogate marker for the development of postoperative PVR. Both postoperative 
measurements could be used by ophthalmologists to monitor inflammation and study 
treatment methods.
In chapter 4 we investigated whether systemic drug use around the time of the RRD 
influenced the development of PVR. In this retrospective study, 1093 patients were included 
who had undergone surgery for RRD between 2006 and 2013 at the Rotterdam Eye 
Hospital. Based on the information in the surgery database patients were divided into three 
groups: uncomplicated course (control group), postoperative PVR and primary PVR. 
Information on their drug use was collected in two ways. For the largest group (mainly 
controls) the information was requested from the Achmea Health Database – one of the 
largest health insurance groups in the Netherlands – and through an anonymization 
procedure coupled to the Eye Hospital database. The remaining group of patients who 
were not insured by Achmea were contacted directly to obtain their permission to request 
their information from their local pharmacy. We were mainly interested in the use of 
antithrombotics, cholesterol lowering agents and ACE-inhibitors. The number of users of 
these drugs was significantly different in the time period before 2010 and after 2010. 
Therefore, the results were presented separately for each time period and this factor was 
included in the logistic regression analysis. We could not detect a significant difference in 
the number of users of these drugs between the different before mentioned patient groups. 
Neither did the logistic regression analysis reveal a significant influence of these drugs on 
the risk of developing postoperative PVR.  
201749 proefschrift Verena Mulder_new_2.indd   126 09-02-18   12:44
127
S U MMARY AN D CONCLUS ION S
5
201749 proefschrift Verena Mulder_new_2.indd   127 09-02-18   12:44
201749 proefschrift Verena Mulder_new_2.indd   128 09-02-18   12:44
Samenvatt ing en conclusies (Nederlands)
6
 
201749 proefschrift Verena Mulder_new_2.indd   129 09-02-18   12:44
130
CHAPTE R 6
Proliferatieve vitreoretinopathie (PVR) is een complicatie die in 5-10% van de patienten met 
netvliesloslating kan ontwikkelen. PVR kan gezien worden als een overdreven littekenreactie 
en wordt gekarakteriseerd door de vorming van membranen die over en onder het netvlies 
groeien, samentrekken en zo het netvlies opnieuw lostrekken. Het operatief verwijderen 
van deze membranen is gecompliceerd en niet altijd mogelijk. Het leidt in de meeste gevallen 
tot verlies van het zicht in dat oog. Het liefst zouden we dus voorkomen dat PVR ontwikkeld, 
echter is dit nog niet zo makkelijk als het lijkt. 
Vanwege de potentiele rol van de stollingsfactor trombine in het ontstaan van PVR zijn we 
gaan kijken naar geneesmiddelen die trombine kunnen remmen. Een geneesmiddel dat 
specifiek trombine remt en sinds 2010 op de Nederlandse markt is is dabigatran (Pradaxa®). 
Dit middel wordt onder andere toegepast ter preventie van trombose bij vervanging van 
een heup of knie en is een oraal alternatief voor de subcutane injecties met bijvoorbeeld 
dalteparine (Fragmin®). Een oraal toepasbaar geneesmiddel heeft als voordeel dat het 
patientvriendelijker is voornamelijk bij herhaalde toediening. Nadelen zijn mogelijke 
systemische bijwerkingen en de vraag of het wel komt op de plek waar het moet werken. 
Dit laatste hebben we onderzocht in hoofdstuk 2.1. Achtentwintig patienten met 
netvliesloslating die een operatie moesten ondergaan kregen twee tot acht uur voor de 
operatie eenmalig 220mg dabigatran. Vervolgens werd er tijdens de operatie glasvocht of 
subretinale vloeistof afgenomen en ter referentie een buisje bloed. De concentratie 
dabigatran werd bepaald met behulp van LC-MS/MS. De resultaten lieten zien dat dabigatran 
wel degelijk in het oog terecht komt, maar wel in veel lagere concentraties dan in het bloed. 
Een onverwachtse bevinding was de concentratie die we vonden in glasvocht van een 
patient die dabigatran dagelijks als therapie gebruikte. Deze concentratie was ongeveer 
10x hoger dan de concentratie na een eenmalige toediening. Dit maakte ons nieuwsgierig 
naar de concentratie na meermalige toediening. In hoofdstuk 2.2 beschrijven we drie 
patienten die allemaal dagelijks dabigatran gebruikten, maar wel voor een andere indicatie 
geopereerd werden aan het glasvocht. Ook in deze patienten zagen we signficant hogere 
concentraties dan dat we zagen na een eenmalige toediening. Maar is dabigatran in staat 
om de effecten van trombine te remmen en zijn de concentraties die we kunnen behalen 
met orale toediening ook voldoende? In hoofdstuk 2.3 hebben we dit onderzocht door 
gekweekte retinaal pigment epitheelcellen (ARPE19) bloot te stellen aan trombine met en 
zonder dabigatran. We vonden dat trombine en trombine-bevattend glasvocht expressie 
van de proinflammatoire cytokinen CCL2, CXCL8, GM-CSF, IL-6 en PDGF-BB induceerde 
wat geremd werd door dabigatran. Daarnaast hebben we gekeken of het glasvocht met 
dabigatran uit de voorgaande studies de trombine activiteit kon remmen. Dit bleek alleen 
te lukken met de hogere concentratie verkregen na herhaalde toediening (12.9 ng/ml). 
In hoodstuk 2.4 hebben we gekeken naar de vorming van trombine door het meten van 
F1+2 en de opruiming van trombine door te kijken naar de vorming van trombine-
antitrombine complex (TAT) in glasvochten en subretinale vloeistof. We zagen dat zowel 
F1+2 en TAT sterk verhoogd waren in patienten met een netvliesloslating ten op zichte 
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van patienten met maculagat of maculapucker. Tussen patienten met en zonder PVR 
konden we door de grote spreiding geen verschil aantonen. Mogelijk spelen het evenwicht 
tussen verschillende regulatiemechanismen van trombine (TAT en α2M) en de algehele 
gezondheid van de patiënt een rol in het risico op het wel of niet ontwikkelen van PVR. 
Een aanvullend mechanisme waarmee dabigatran mogelijk kan bijdragen aan het voorkomen 
van PVR is het verminderen van de vorming van α2M gebonden trombine, door het 
verplaatsen van het evenwicht naar de vorming van inactief TAT. 
De resultaten van hoofdstuk 2 samengevat lijkt dabigatran de potentie te hebben om 
intraoculair trombine te remmen en is interessant genoeg om verder te onderzoeken als 
potentieel middel ter voorkoming van PVR. Echter gezien de mogelijk ernstige bijwerkingen 
die kunnen optreden bij het gebruik van middelen zoals dabigatran is het gewenst die 
patienten te selecteren die het hoogste risico lopen op het ontwikkelen van PVR en dus 
ook het meeste baat zouden hebben bij een geneesmiddeltherapie. 
Hoofdstuk 3 beschrijft de toepassing van het meten van “flare” in de voorste oogkamer 
als voorspeller van postoperatief PVR. Flare is een fenomeen dat ontstaat door reflectie 
van licht op deeltjes, zoals ontstekingseiwitten, en kan vergeleken worden met een 
lichtstraal in een donkere rokerige kamer waardoor deeltjes zichtbaar worden. Het is een 
objectieve maat voor inflammatie. Eerder onderzoek vond dat een hoge flare waarde, 
preoperatief gemeten met behulp van een Kowa laser flare meter, voorspellend was voor 
het postoperatief ontwikkelen van PVR. Herhaling van deze studie in een cohort uit 
Rotterdam en een cohort uit Kiel (Duitsland), beschreven in hoofdstuk 3.1, kon deze 
voorspellende waarde echter niet bevestigen. We combineerden de data van twee 
onafhankelijke prospectieve studies: Kiel (120 patienten) en Rotterdam (194 patienten). 
PVR werd gedefinieerd als een nieuwe netvliesloslating ten gevolge van tractiemembranen 
binnen zes maanden na de eerste loslating, waarvoor heroperatie noodzakelijk was. Met 
behulp van logistische regressie en ROC-analyse bekeken we of een hogere preoperatieve 
flare waarde geassocieerd was met een hogere kans op het ontwikkelen van PVR. 
PVR ontwikkelde in 21/314 patienten (6.7%). De mediane flare waarden verschilde 
signficant tussen de twee centra waarop besloten is de analyses voor elk centrum apart 
uit te voeren. De logistische regressieanalyse liet alleen voor Rotterdam een klein maar 
signficante verhoging van het risico zien bij een hogere flare waarde (OR 1.014; p=.005). 
De oppervlakte onder de ROC-grafiek liet een lage sensitiviteit en specificiteit zien: Kiel 
0.634(95% CI: 0.440 – 0.829) en Rotterdam 0.731(95% CI: 0.598 – 0.865). Daarnaast gaf 
de gerapporteerde afkapwaarde van 15 pc/ms uit de eerdere studie in combinatie met de 
lage prevalentie in onze studie slechts een positief voorspellende waarde van 12%. Op 
basis hiervan concluderen we dat preoperatief gemeten flare niet nauwkeurig genoeg is 
om onderscheid te kunnen maken tussen patienten met een laag en een hoog risico op 
het ontwikkelen van postoperatieve PVR. 
 Aangezien de operatie voor de netvliesloslating zelf mogelijk ook bijdraagt aan inflammatie 
en dus de hoogte van de flare waarde, is in hoofdstuk 3.2 gekeken of de postoperatieve 
201749 proefschrift Verena Mulder_new_2.indd   131 09-02-18   12:44
132
CHAPTE R 6
flare waarde een voorspeller of surrogaatmarker was voor het ontwikkelen van PVR. In 
195 patiënten met een primaire rhegmatogene netvliesloslating is flare gemeten twee en 
zes weken na de operatie. Hierbij vonden we dat de mediane flarewaarde in de patiënten 
die postoperatief PVR zouden gaan ontwikkelen, zowel op twee als zes weken na de 
operatie, significant hoger was dan bij patiënten met een ongecompliceerd beloop (mediaan 
2wkn: 43 vs. 15 pc/ms; p =0.001, mediaan 6wkn: 38 vs. 13 pc/ms; p < 0.001). Ook de 
logistische regressie en de ROC-analyse lieten een voorspellende waarde zien van de 
flaremeting.  
De individuele verandering van de flarewaarde na de operatie ten opzichte van de 
flarewaarde voor de operatie liet geen duidelijke trend zien. Voor de meeste patiënten met 
een ongecompliceerd beloop steeg de flarewaarde na de operatie minder dan 10 pc/ms. 
Van de patiënten die later PVR zouden ontwikkelen ging in de helft van de patiënten de 
flare waarde omhoog en in de andere helft de flare waarde omlaag. De richting van de 
verandering lijkt dus minder van invloed dan de absolute flarewaarde die overblijft na de 
operatie. De operatie zelf lijkt hier dus ook van invloed te zijn op de uitkomst. Dit wordt 
verder bevestigd in hoofdstuk 3.3 waarin duidelijk wordt dat een vitrectomie procedure 
een hevigere postoperatieve inflammatie tot gevolg heeft dan een cerclage/plombe 
procedure, onafhankelijk van de grootte van de netvliesloslating.  
In conclusie, de postoperatieve flarewaarde van twee weken na de operatie is een redelijke 
surrogaatmarker voor de ontwikkeling van postoperatieve PVR. Beide metingen, los of in 
combinatie zouden gebruikt kunnen worden om inflammatie te monitoren en mogelijk het 
effect van nieuwe therapieën te bestuderen.
In hoofdstuk 4 hebben we onderzocht of systemisch geneesmiddelgebruik rondom het 
ontstaan van een netvliesloslating mogelijk van invloed zou kunnen zijn op het wel of niet 
ontstaan van PVR. In dit retrospectieve onderzoek zijn 1093 patiënten geïncludeerd die 
tussen 2006 en 2013 geopereerd zijn in het Oogziekenhuis Rotterdam voor een primaire 
netvliesloslating. Op basis van gegevens uit de operatiedatabase zijn deze patiënten 
opgedeeld in drie groepen, te weten ongecompliceerd beloop (controlegroep), postoperatief 
PVR en primair PVR. De geneesmiddelgegevens van deze patiënten zijn vervolgens op 
twee manieren verzameld. Voor de grootste groep (voornamelijk controles) zijn de gegevens 
opgevraagd via de Achmea Health Database – een van de grootste zorgverzekeraars in 
Nederland – en via een pseudonimisatie procedure gekoppeld aan het Oogziekenhuis 
bestand. De resterende groep patiënten, die niet bij Achmea verzekerd was, is persoonlijk 
benaderd en gevraagd om toestemming voor het opvragen van hun gegevens bij hun lokale 
apotheek. We hebben vooral gekeken naar het gebruik van antitrombotica, 
cholesterolverlagende middelen en ACE-remmers. De resultaten lieten een significant 
verschil zien tussen het aantal gebruikers van deze geneesmiddelgroepen in de periode 
voor 2010 en de periode na 2010. De gebruikscijfers zijn daarom uitgesplitst naar tijdvak 
en het tijdvak is meegenomen als factor in de logistische regressie analyse. We konden 
echter geen significant verschil aantonen tussen bovengenoemde patiëntgroepen in het 
201749 proefschrift Verena Mulder_new_2.indd   132 09-02-18   12:44
133
SAM E NVATTI NG E N CONCLUS I E S
6
aantal gebruikers van antitrombotica, cholesterolverlagende middelen en ACE-remmers. 
Ook liet de logistische regressie analyse geen significante invloed zien van deze 
geneesmiddelgroepen op het ontwikkelen van postoperatieve PVR.
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The development of proliferative vitreoretinopathy is still the major cause of failure of retinal 
reattachment surgery. While initially there is little difference between patients with 
uncomplicated RD and patients who later develop PVR, in some patients, something 
triggers the derangement of the healing process. PVR could be considered an exaggerated 
response of the active tissue remodelling process triggered by the injured retina. Despite 
great effort, no relevant advances in clinical management have been made in the last 40 
years.1 
We wished to study a potential new treatment; as any treatment has side-effects, we also 
wished to find a way to identify only patients at risk.
Recently, coagulation proteins were implicated in the development of PVR.2 Activation of 
the coagulation cascade plays a central role in the tissue healing process but dysregulation 
has been recognised to contribute to fibrosis in lung, liver and kidney.3-5  Interference with 
the coagulation cascade, with a long history of drugs in clinical use, would therefore, appear 
to be a good therapeutic target. 
In chapter 2 we tested whether the oral direct thrombin inhibitor dabigatran would be a 
potential drug candidate for the treatment of PVR. Our decision to explore the potential of 
dabigatran instead of other coagulation inhibitors had several reasons. Dalteparin – an 
LMWH which has been previously tested in clinical use or clinical trials6-12– needs the 
presence of antithrombin (AT) to inactivate factor Xa and/or thrombin. It was unclear 
whether AT would be present in vitreous and we therefore measured the concentration 
of AT in a few vitreous samples of patients with RD with and without PVR. The 
concentrations were much lower than in normal plasma (< 0.10 U/ml vs. 0.40-1.40 U/mL) 
(unpublished data 2013). In addition, while LMWH’s have a weaker inhibitory effect on 
thrombin than on factor Xa, the results of Bastiaans et al revealed that thrombin was a 
more potent inducer of inflammatory and fibrotic changes than factor Xa.13 We, therefore, 
shifted our attention to the direct thrombin inhibitors. 
The naturally occurring most potent inhibitor of thrombin is the peptide hirudin which is 
produced by leeches. Hirudin is not registered for use in humans but there are several 
drugs that are derived from it using recombinant biotechnology, such as bivalirudin and 
lepirudin. In addition, small molecule direct thrombin inhibitors have been chemically 
synthesised such as argatroban and dabigatran. To date, only bivalirudin, argatroban and 
dabigatran are registered in the Netherlands. The former two are available as intravenous 
injections/infusion and have a relatively short half-life of 25 and 50 minutes respectively.14, 
15 Dabigatran, on the other hand, is an oral drug with a plasma half-life of approximately 12 
hours.16 As PVR has a protracted course and usually develops between 4 and 12 weeks 
after surgery17 a single administration or single exposure during the vitrectomy procedure 
is probably not sufficient. While local administration is generally preferred, an oral drug is 
more patient friendly when therapy is extended. An additional advantage of dabigatran is 
that it is not only registered for treatment purposes but also for prevention. We, therefore, 
explored dabigatran as a potential drug candidate for the treatment of PVR.  
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POTENTIAL OF DABIGATRAN
Oral administration, however, has several disadvantages. Firstly, it is questionable whether 
the drug reaches the target site in the eye via the systemic route and, if it does so, whether 
it reaches a sufficiently high concentration. We hypothesised however that in the case of 
a retinal detachment the retinal barrier is disrupted and the eye would, therefore, be more 
permeable to drugs. Interestingly, diffusion of dabigatran into the vitreous was not limited 
to a disrupted retinal barrier. As was shown in chapter 2.2 also in patients with a macular 
hole or dropped nucleus dabigatran reached quantifiable levels after repeated 
administration.18 Research by Weijtens et al had already shown this for dexamethasone.19 
Concentration of dabigatran was even higher when formed vitreous had been previously 
removed and was replaced with aqueous.18, 20 As dabigatran is a highly hydrophilic 
compound it is unsure whether this would also be true for other (more hydrophobic) 
substances.    
Although the concentrations we found were low compared to plasma concentrations, the 
theoretically needed concentration was (almost) met after repeated administration and 
chapter 2.3 showed that this concentration could diminish thrombin activity. Moreover, the 
amount of thrombin measured is most likely not active all at once but represents 
accumulation in the vitreous (chapter 2.4). Therefore, sustained levels of dabigatran might 
be more effective. 
Determining the starting point and optimal duration of therapy is difficult. Ideally, one would 
like to start as soon as one knows that a patient is at high risk of developing PVR. This is, 
however, as described in chapter 3, not easy. Previously described oral treatments were 
prescribed during 10 and 15 days and 7, 4 and 8 weeks.21-25 The rationale for the chosen 
duration, however, is not described. The onset of PVR, however, is usually between 2 
weeks and 6 months after RD, with a median of 2 months.26 Earlier research showed that 
the blood-aqueous barrier returned to normal within 8 weeks and also our own flare 
measurements suggest that in uncomplicated patients it returns to normal within this 
period.27-29 Dabigatran is registered for the prevention of knee and hip replacement surgery 
in a duration of 10 days and 28-35 days starting 1-4 hours after surgery respectively.16 The 
latter duration would be a good starting point for further clinical research.  
SAFETY OF DABIGATRAN
A second disadvantage of systemic drug administration is that all organs of the body are 
exposed to the drug while only a small part of the eye needs the treatment. This increases 
the risk of side effects and interaction with other systemic drugs. The risk of bleeding is 
increased when patients have underlying conditions with increased bleeding tendency or 
when the plasma level of dabigatran increases due to factors such as reduced renal 
clearance (30-50 ml/min), age > 75 years, body weight < 50kg and/or combination with 
P-gp inhibitors.16 Also the concomitant use of other anticoagulant drugs, NSAIDS and SSRI’s 
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increase the risk of bleeding. Dabigatran should therefore not be blindly prescribed to every 
patient at risk for developing PVR. In our first study, we excluded patients with these risk 
factors and no adverse events were reported after a single administration. Repeated 
administration would possibly pose more risk. Most patients, however, are subjected to a 
preoperative screening by an anesthesiologist whom checks and reports the above-
mentioned risk factors. In most cases the dosage could be reduced as is described for 
knee and hip replacement surgery from 220 mg once daily to 150 mg once daily. 
In addition, since 2015 there is – in case of excessive bleeding – an antidote available in 
the form of a monoclonal antibody named idarucizumab (Praxbind®).30  
RISK ASSESSMENT
A large part of this thesis focused on the evaluation of aqueous laser flare measurements 
as a predictor for the development of PVR. Laser flare measurements were reported by 
Schröder et al to strongly predict the development of PVR.31 A flare value above 15 pc/ms 
would increase the risk by 16 times. Several other groups repeated this study, including 
us, and we therefore decided to combine the results with the research group from Kiel 
(Germany). As the number of PVR cases was lower than expected in both centres this 
would be an elegant way to increase statistical power. Unfortunately, the differences in 
flare values between the two centres were too large and we therefore decided to analyse 
the results separately. The conclusion for both centres was that flare values of 
uncomplicated and PVR cases overlapped too much to define a clear cut-off point with 
high enough sensitivity, specificity and positive predictive value. We were unable to 
reproduce the previously published results. 
A possible explanation for the discrepancy with the previous reports is our low prevalence 
of postoperative PVR (7.5% and 6.2%) compared to the previous reports.32 All previous 
reports included consecutive patients and found prevalences of 10.3%31, 14.9%33 and 20% 
34. Both the positive predictive value (PPV) and the odds ratio (OR) are affected by the 
prevalence. This means that even with comparable sensitivity and specificity the PPV and 
the OR will be lower when the prevalence is lower. In addition, different reports used 
different definitions of postoperative PVR. We used reoperation due to epiretinal 
membranes and/or subretinal strands within six months of initial surgery, as did Schröder 
et al.31 Hoerster et al. based their findings on PVR grade C at 3 months postoperatively. 
While ten patients developed PVR only four (6%) needed a reoperation.33 It is unclear from 
the report whether all four patients had a flare value > 15 pc/ms but if this were the case 
this would give a PPV of 20% and OR of 8 instead of the reported 40% and 30. Conart et 
al. used PVR grade B and C at 6 months as the outcome. Moreover, 20% of the included 
patients had preoperative PVR grade C which influenced the postoperative number of 
patients with PVR. 
The predictive value of the flare value thus depends on the patient group that is targeted. 
Our results indicate that there is a large overlap in flare values which makes selecting those 
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patients at high risk for developing postoperative PVR according to our definition 
inaccurate.32 Dependent on the implications of a positive test result (flare value > 15pc/
ms) we should decide whether a false discovery rate of 60-90% is acceptable. 
The measurement of postoperative flare values revealed that the type of surgery and events 
during surgery significantly influence the inflammatory response and thus possibly the risk 
of developing PVR. Postoperative flare values showed stronger predictive properties than 
the preoperative values but the positive predictive value remained relatively low.  In addition, 
waiting two to six weeks to start a possible treatment might pass the window of opportunity 
to intervene in the process. Postoperative flare measurements would be useful in the 
follow-up of patients both in clinical practice and in studying the effect of treatment 
methods. 
FUTURE PERSPECTIVES
The results in this thesis indicate that dabigatran is an interesting drug candidate that should 
be further explored for its potential in the prevention of PVR. 
However, to initiate a clinical trial to test the efficacy of dabigatran in the prevention of PVR 
seems premature. As PVR occurs in approximately 6% of patients with RD the number of 
patients needed to obtain enough statistical power to prove a 50% reduction in the PVR 
rate is well over 1500 patients. The question is whether the uncertain benefits and unknown 
optimal dosing regimen at this point outweigh the risks of exposing many patients 
unnecessarily to dabigatran. This is probably the main reason why previous research often 
included patients with established PVR. Because the coagulation cascade is activated at 
an early stage after retinal detachment it is unlikely that intervention with dabigatran will 
be effective after established PVR. 
Another possibility could be to test the effect of dabigatran in an animal model. Over 27 
animal models have been described.1, 35 The most widely used animal models are pigmented 
rabbits which received an intravitreal injection with a specific cell type such as fibroblasts, 
RPE-cells or activated macrophages. Other models included surgical manipulation such as 
lensectomy, vitrectomy, cryotherapy or penetrating trauma.1, 35 However, positive results 
found in these animal models did not translate into success in patients. 
Possible reasons are the single cell-type/factor nature of the models while new insights 
have shown other origins of the cells involved and point to a multifactorial pathogenesis. 
In addition, the difference between humans and rabbits in vascularisation scheme and cell 
composition of the retina might add to differences in experimental results. Animal models 
are of value in studying specific features of PVR and help in unravelling the pathogenesis. 
However, as PVR is a multifactorial disease and is likely to be a result from the interaction 
of genetic and environmental factors, these models seem unsuitable for testing new drug 
therapies.1
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5-FU Fluorouracil
a2M Alpha-2-Macroglublin
ARPE-19 Human retinal pigmented epithelial cell line
ASA American Standardisation Association
AT Antithrombin
AUC Area under de curve
BAB Blood aqueous barrier
BOB Blood ocular barriers
BQL Below quantification limit
BRB Blood retinal barrier
C3F8 Octafluoropropane
CCL C-C motif chemokine ligand
Cmax Maximum concentration
CXCL C-X-C motif chemokine ligand
Da Dalton
DTI Direct thrombin inhibitor
dTT Diluted thrombin time
ECM Extracelluar matrix
F1+2 Prothrombin fragments (F1+2)
FCS Fetal calf serum
FGF Fibroblast growth factor
GM-CSF Granulocyte-macrophage-colony-stimulating factor 
HPLC High Performance Liquid Chromotography
IFN Interferon
IL Interleukin
ILM internal limiting membrane
IOP Intra ocular pressure
LC-MS/MS Liquid chromatography–tandem mass spectrometry
LDH Lactate dehydrogenase 
LLQ Lower limit of quantification
MHOLE Macular hole
MPCK Macular pucker
MW Molecular weight
NSAID Non-steroidal antiinflammatory drug
OD Optical density
OR Odds ratio
PAR Protease-activated receptor
PDGF Platelet-derived growth factor
PPI Proton pump inhibitor
PPP Platelet poor plasma
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LIST OF ABBR EVIATION S 
PPV Pars plana vitrectomy
ppv Positive predictive value
PVR Proliferative vitreoretinopathy
QL Quantification limit
RD Retinal detachment
ROC Receiver operating characteristic
RP Reversed phase
RPE Retinal pigment epithelium
RQ-PCR Real-time quantitative polymerase chain reaction
RRD Rhegmatogenous retinal detachment
SB Scleral buckling
SD Standard deviation
SF6 Sulfur hexafluoride
SRF Subretinal fluid
SSRI Selective serotonin reuptake inhibitor
STR Short tandem repeat
TAT Thrombin- antithrombin complex
TBS Tris-buffered saline 
TNF Tumour necrosis factor 
ULQ Upper limit of quantification
VEGF Vascular endothelial growth factor
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Nooit had ik gedacht dat ik met een promotietraject zou starten, laat staan deze te voltooien! 
Maar de mogelijkheid dit in het Oogziekenhuis Rotterdam te doen en ook nog eens te 
combineren met farmacie kon ik niet voorbij laten gaan. 
Toen ik vertelde dat ik naar Rotterdam ging verhuizen verklaarden de meeste mensen in 
mijn omgeving mij voor gek. Rotterdam?! Weet je het zeker? Heel zekert!
Ik heb geen moment spijt gehad van dit avontuur en dat is geheel te danken aan alle fijne 
mensen in mijn leven! 
Jullie hebben elk op een eigen manier bijgedragen aan het feit dat ik hier sta vandaag. 
Allereerst dank aan alle patiënten die belangeloos hebben meegewerkt aan de verschillende 
onderzoeken in dit proefschrift. Het is namelijk niet niks wanneer je net te horen hebt 
gekregen dat je aan je oog geopereerd moet worden – omdat je anders je zicht verliest – 
ook nog eens ja te zeggen tegen extra metingen of studiemedicatie. Dank daarvoor! 
Dank aan mijn promotor Prof. Dr. Jan van Meurs. Beste Jan, bedankt dat je het aandurfde 
met een apotheker. Dat was voor beide een beetje wennen. Ineens zat ik naast je achter 
de microscoop en mocht ik hechtingen knippen en met een sigaar het oog deppen. Ik vond 
het doodeng, maar stiekem ook wel erg leuk. Ik bewonder je creatieve en vrije geest en 
je passie voor onderzoek. Ik hoefde dan ook nooit lang te wachten op inhoudelijke feedback. 
Je reageerde altijd enthousiast met opbouwende kritiek. Dat stimuleerde mij om verder 
te gaan. 
Dank aan mijn copromotor Dr. Ellen la Heij. Beste Ellen, op de valreep kwam je als mijn 
copromotor aan boord. Bedankt voor je doortastende en praktische adviezen!
De overige chirurgische retinaspecialisten: Koen van Overdam, Koorosh Faridpooya, Erik 
Lindstedt, Peter van Etten, Joeri de Hoog en Marc Veckeneer. Dank voor jullie hulp bij het 
verzamelen van glasvocht en het mij wegwijs maken in de netvliesaandoeningen. Ik heb 
genoten van het meekijken op de OK. Daarbij wil ik ook de anesthesisten, anesthesie- en 
OK-assistenten bedanken voor hun hulp bij het verzamelen van materiaal en het mij wegwijs 
maken op de OK.  
Dank aan Prof. Dr. Cornelis Kluft. Beste Kees, hartelijk dank voor je input op onze 
experimenten en het delen van je expertise op stollingsgebied.  
Daarnaast ook dank aan Dr. Netty Dorrestijn, voormalig managing director. Beste Netty, ik 
belde jou om te vragen of ik als apotheker ook kon solliciteren op deze plek die eigenlijk 
uitgeschreven was voor een arts. Daar hadden jullie niet aan gedacht, maar waarom 
eigenlijk ook niet? Bedankt voor je begeleiding en ondersteuning. 
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Dank aan de dames en heer op de verpleegafdeling. Ik heb heel wat uurtjes bij jullie 
doorgebracht in mijn donkere kamertje en daarbuiten bij jullie op de afdeling. Bedankt voor 
jullie hulp en gezelligheid.  
Beste Elon, Ida en Olympia, jullie hebben ook ontzettend veel werk verricht met het 
includeren van patiënten, meten en data invoeren. Dank voor alle hulp en gezelligheid!
Beste Jeroen, glasvocht en -80°C vriezer, twee woorden die eigenlijk symbool staan voor 
onze relatie. Als promovendi op hetzelfde project – jij op het lab en ik in de kliniek – brachten 
wij redelijk wat tijd door bij de -80°C vriezer in de kelder op zoek naar glasvocht. Dank voor 
onze fijne discussies en samenwerking. 
Mijn kamergenoten in chronologische volgorde Sankha, Gijs, Robin, Babak en Lisette. We 
hebben wat lief en leed met elkaar gedeeld in kamer 4.26 en daarbuiten.  Ik weet niet wat 
ik zonder jullie had gemoeten, bedankt voor deze tijd! 
Stijn, wij begonnen rond dezelfde tijd en waren beide nieuw in Rotterdam. Samen mochten 
wij o.a. op GMP-cursus naar Barcelona en op congres naar Orlando. Dat schepte een band! 
Inmiddels zijn we vele gezellige (stap) avondjes verder en ben je geen collega meer maar 
vriend. Dank!
Eva, ik had niets met hardlopen tot het moment dat ik met jou de Eye Care Loop ging 
organiseren. Jouw enthousiasme werkt aanstekelijk! Zeker acht maanden per jaar waren 
we druk met sponsoring, activiteiten organiseren en lopers motiveren met als hoogtepunt 
de loop tijdens de Marathon van Rotterdam en een mooi geldbedrag voor het goede doel. 
Een ding heb ik eraan overgehouden... het gebruik van uitroeptekens!!  Ik heb bewondering 
voor jouw talent om mensen te motiveren. Dank voor je vriendschap.
Dank aan al mijn andere collega’s van het ROI! Aline, Angela, Arni, Elrozy, Esma, Grzegorz, 
Henk, Juan Pedro, Jelena, Juleke, Kari, Kedir, Laurence, Saskia, Sonia en Susan. Annemiek, 
Caroline, Jetty, Koen, Marja en Rene – onze seniors. Qua wijsheid uiteraard en niet hun 
geest. Bedankt voor al jullie advies en ondersteuning. Jullie zijn de backbone van het ROI! 
Het was een feestje om met jullie allen te mogen werken en als het aan mij ligt houden 
we de borreltraditie erin!
En dan de mensen buiten het Oogziekenhuis... waar te beginnen? Bij mijn oudste vriendin 
dan maar. 
Beste Yvonne, sinds groep 3 zijn wij bevriend en hebben we al veel met elkaar beleefd. 
Ondanks dat onze levens totaal van elkaar verschillen weten we elkaar altijd te vinden. Ik 
kan bij jou en Sander altijd op de bank ploffen om even bij te komen en helemaal niets te 
hoeven. Dank dat jullie altijd voor me klaar staan. 
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Annemarie, Sanne, Michel, Kevin en Stefan, al sinds de middelbare school zijn wij bevriend. 
De vele avonden in café Bordeaux en onze vakantie naar Hongarije zijn nog steeds een 
bron voor goede verhalen. Inmiddels is ons clubje uitgebreid met aanhang Ogi, Rob, Erika, 
Valerie en Vera. We zien elkaar veel te weinig, maar als we bij elkaar zijn voelt het als 
vanouds. Jullie vriendschap is mij dierbaar! 
Stefan, bedankt dat jij vandaag mijn paranimf wil zijn! 
Lieke, samen op de bar met een afwasborstel om onze nek tijdens introductiekamp, dat 
is mijn eerste herinnering aan jou. Je bent open, eerlijk en altijd in voor een feestje. Ik kijk 
met veel plezier terug op onze fantastische stage op Aruba. Marijn, wij ‘bonden’ tijdens 
een schoonmaak dansje op het lab waarna nog vele (dans) avondjes volgden. Ik kan met 
niemand zo ouwehoeren als met jou. Dank voor de vele opbeurende gesprekken!
Miranda, bijna vanaf het begin van de studie trekken wij samen op. Lab partners, stage, 
buitenlandexcursie en vakanties samen. Je bent ontzettend slim, kritisch, nauwkeurig en 
behulpzaam. Bijna 4 jaar geleden mocht ik jou bijstaan, dank dat jij voor mij hetzelfde wil 
doen!
Claudia, ruim 10 jaar geleden ontmoetten we elkaar in Edinburgh maar werden pas echt 
bevriend toen je naar Utrecht kwam. Ik vind het zo knap hoe makkelijk jij je aanpast en de 
mensen om je heen betoverd. Je leerde binnen no-time vloeiend Nederlands, verzamelde 
een hoop vrienden en verdedigde afgelopen november succesvol je eigen proefschrift. 
Dank voor de vele gesprekken, foute feestjes, oh zo nodige spa-dagen en leuke vakantie 
samen. 
Het is alweer 10 jaar geleden dat ik kwam wonen op G8. Jiska, Steven, Ward en Wouter, 
het was een feestje om met jullie te wonen! Onze Sinterklaasavondjes met de meest foute 
cadeaus zijn inmiddels een traditie. Ik kijk er elk jaar weer naar uit!
Ook de Winterswijkse/Rotterdamse crew mag natuurlijk niet ontbreken in het rijtje. Lars, 
Thirza, Leon en Irès. Sinds een aantal jaar mag ik jullie mijn vrienden noemen en hebben 
we al aardig wat mooie vakanties in Bulgarije, Italië en Giethoorn beleefd. Ook de jaarlijks 
terugkerend feestjes als Dreamfields, Zwarte Cross en Volksfeest zorgden voor ontspanning 
tijdens de af en toe stressvolle tijden. Dank voor jullie gezelligheid!
Beste Joke, Willy, Marieke, Barry, Petra, Erik en kids, dank dat jullie me hebben opgenomen 
in jullie familie. Dank voor jullie hulp, adviezen en vooral gezelligheid! Ik hoop dat er nog 
vele mooie momenten mogen volgen!
Lieve familie, a.k.a. de leukste familie. Truus, Wim, Itske, Hendrik, Marja, Ruud, Mirella, 
Taede, Senn, Sander, Angelique, Larissa, Rozanna en Kylian. Ook al wonen we inmiddels 
wat verder uit elkaar (tot zelfs in Berlijn) en zien we elkaar veel te weinig, samen kerst 
vieren is traditie! Veel te veel eten, een potje 31-en en op de foto in een foute kersttrui. 
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Ook kijk ik met veel plezier terug op ons bijzondere neven en nichten weekend in Berlijn 
en moeder-dochter weekend in Milaan. Ik ben blij dat jullie mijn familie zijn!
Lieve Coen, wat had ik zonder jou gemoeten! Het is niet één, maar meerdere keren 
voorgekomen de afgelopen jaren dat ik je in paniek opbelde omdat mijn harde schijf of 
computer gecrasht was en daar toch al mijn belangrijke bestanden op stonden. Elke keer 
nam je mijn computer over (onder gemompel nog steeds geen back-up zeker?!) en al 
duurde het uren of dagen je wist mijn bestanden altijd weer te redden. Je staat altijd voor 
ons klaar en ik ben trots dat jij mijn broer bent!
Pap, de jaarlijkse tripjes met mam naar jou in Amsterdam en jouw levendige verhalen over 
wat je allemaal meemaakt in de winkel zijn waarschijnlijk de reden van mijn fascinatie voor 
ogen. Ik vond het fantastisch om je bezig te zien in de werkplaats met al die mallen, kleine 
tangetjes en schroevendraaiertjes. En altijd weer de spannende ogentest met de phoropter. 
Het heeft een diepe indruk gemaakt. Al 45 jaar werk je daar en al bijna 12 jaar zijn jullie de 
eigenaar. Ik ben super trots dat jullie die stap hebben gezet en dat zo goed samen doen. 
Jullie vonden het vaak lastig om mij inhoudelijk te helpen, maar hebben mij altijd op elke 
mogelijke manier ondersteund en gestimuleerd. 
Lieve pap en mam, bedankt voor jullie rotsvaste vertrouwen in mijn kunnen en dank dat 
jullie er altijd voor me zijn. 
En tenslotte mijn liefste. Je bent mijn knuffelbeer en rots in de branding. Ik bewonder je 
optimisme, gedrevenheid en gewoon doen mentaliteit. Het is met jou nooit saai.. zo had 
ik nooit gedacht dat we zo’n grote verbouwing zelf zouden doen, maar ben wel trots op 
het resultaat. En als het me soms allemaal wat te veel werd waren jouw kopjes thee, 
kookkunsten en taxiservice naar het ozr onmisbaar voor mij. 
Lieve Roel, de afgelopen jaren waren niet zonder uitdagingen, maar samen kunnen we 
volgens mij alles aan. Bedankt dat jij de mijne bent!
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